Patent Grant
9737561
The present invention relates to topical gels that may controllably release nitric oxide. The present invention also relates to methods of using topical gels that may controllably release nitric oxide.
Skin has a myriad of functions, including protection against pathogens and excessive water loss, insulation, temperature regulation, sensation and protection of vitamin B folates. As such, impairment or ailments of the skin may significantly affect the health of a person or animal. Furthermore, such impairments or ailments may cause irritation, pain or other discomfort and may undesirably affect the person or animal's physical appearance.
An important aspect for the treatment of many skin impairments or ailments, including wounds and burns, is the control of infection, which may facilitate the healing process. Topical medicaments are commonly used tools to protect wounds and other skin ailments from infection. Antimicrobial agents are often incorporated into topical medicaments and wound dressing to treat and prevent infection. However, there may be disadvantages associated with use of antimicrobial agents. It has been observed that an increasing number of pathogens have developed resistance to conventional antibiotic treatments. According to statistics, antibiotic-resistant pathogens are the primary reason for a majority of all lethal nosocomial infections. See Robson et al., Surg. Clin. N. Am. 77, 637-650 (1977). Furthermore, many antimicrobial agents not only kill pathogens, but also impose a threat to the proliferating granulation tissue, fibroblasts and keratinocytes that may help with the wound healing process. Additionally, some antimicrobial agents may cause allergic reactions in some patients.
It is known that nitric oxide possesses a broad-spectrum of antimicrobial activity and may be used as an alternative to conventional antibiotics for drug resistant bacteria. Furthermore, some recent studies have demonstrated that nitric oxide may also play an important role in the wound healing process by promoting angiogenesis through stimulation of vascular endothelial growth factor (VEGF) and increase fibroblast collagen synthesis. See Schaffer M R, et al., Diabetes-impaired healing and reduced wound nitric oxide synthesis: A possible pathophysiologic correlation. Surgery 1997; 121(5):513-9; and Shi H P, et al., The role of iNOS in wound healing. Surgery 2001; 130 (2):225-9. Thus, nitric oxide presents a promising addition and/or alternative to the conventional antibiotic treatments. Furthermore, nitric oxide has been shown to have other beneficial properties, including reducing inflammation and participation in wound healing biochemical cascades. Unfortunately, the relationship between exogenously applied concentrations of nitric to promote healing, mediate inflammation, or treat infection are not clearly understood.
Nitric oxide is a gas at ambient temperature and atmospheric pressure, and it has a short half-life in a physiological milieu. Several small molecule nitric oxide donor prodrugs have been developed which have contributed greatly to the understanding of nitric oxide in a number of disease states. However, due to their issues with stability, indiscriminate NO-release, monotypical nitric oxide release kinetics, and inability to target specific tissue types, optimal solutions for administering nitric oxide outside of its gaseous form have not yet been achieved. Reproducibly delivering the correct levels of nitric oxide for a given therapeutic indication is critical because the release of large amounts of nitric oxide may be toxic or create undesirable side effects such as an increase in inflammation. Therefore, it has been challenging to use nitric oxide for topical therapeutic applications, particularly for reproducibly delivering nitric oxide in a controlled manner from vehicles capable of targeting tissue structures.
As an example, previous investigators have explored the use of topical formulations containing an alkali nitrite source in combination with ascorbic acid or other organic acid, that upon admixture or mixing create a rapid bolus of nitric oxide release. While the antimicrobial efficacy of nitric oxide released via this approach has been shown, it may also result in decrease in angiogenesis, increase in inflammation and unwanted toxicity. Thus, the need exists for topical treatments and medicaments that can release nitric oxide by a controlled delivery method.
Provided according to embodiments of the invention are topical gels that release nitric oxide (NO). In some embodiments of the invention, the topical gels include diazeniumdiolate-functionalized polysiloxane macromolecules and a hydrophobic, non-aqueous gel base. In some embodiments, the hydrophobic, non-aqueous gel base is a silicone gel. Furthermore, in some embodiments, the diazeniumdiolate-functionalized polysiloxane macromolecules and gel excipients have an octanol/water partition coefficient in a range of 0.1 to 7.
In some embodiments of the invention, the topical gels include diazeniumdiolate-functionalized polysiloxane macromolecules and a hydrophilic gel base. As such, in some embodiments, the diazeniumdiolate-functionalized polysiloxane macromolecules and the gel excipients have an octanol/water partition coefficient in a range of −2 to 0.
In some embodiments of the invention, the concentration of the diazeniumdiolate-functionalized polysiloxane macromolecules in the gel is in a range of 0.1 to 20 weight %.
In some embodiments of the invention, the diazeniumdiolate-functionalized polysiloxane macromolecules have a hydrodynamic radius in a range of 1000 nm to 10 microns. In some embodiments of the invention, the diazeniumdiolate-functionalized polysiloxane macromolecules have a hydrodynamic radius in a range of 1 nm to 100 nm.
The nitric oxide storage of the gels may be tailored. In some embodiments, the nitric oxide storage per gram is in a range of 0.1 pmol NO/g to 100 nmol/g gel. In some embodiments, the nitric oxide storage per gram is in a range of 1 nmol NO/g to 10 μmol/g gel. In some embodiments, the nitric oxide storage per gram is in a range of 10 μmol NO/g to 1 mmol/g gel.
In some embodiments of the invention, the gels further include other therapeutic agents such as an anti-acne agent, antimicrobial agent, benzoyl peroxide, or a corticosteroid.
Also provided herein are methods of treating wounds that include wound comprising applying the topical gel according to an embodiment of the invention. In particular embodiments, methods include treatment of burns and treatment of acne.
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this application, illustrate certain embodiment(s) of the invention.
The foregoing and other aspects of the present invention will now be described in more detail with respect to the description and methodologies provided herein. It should be appreciated that the invention can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the embodiments of the invention and the appended claims, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Also, as used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items. Furthermore, the term “about,” as used herein when referring to a measurable value such as an amount of a compound, dose, time, temperature, and the like, is meant to encompass variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the specified amount. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. Unless otherwise defined, all terms, including technical and scientific terms used in the description, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
All patents, patent applications and publications referred to herein are incorporated by reference in their entirety. In the event of conflicting terminology, the present specification is controlling.
The embodiments described in one aspect of the present invention are not limited to the aspect described. The embodiments may also be applied to a different aspect of the invention as long as the embodiments do not prevent these aspects of the invention from operating for its intended purpose.
As used herein the term “alkyl” refers to C1-20 inclusive, linear (i.e., “straight-chain”), branched, or cyclic, saturated or at least partially and in some cases fully unsaturated (i.e., alkenyl and alkynyl) hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and allenyl groups. “Branched” refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain. Exemplary branched alkyl groups include, but are not limited to, isopropyl, isobutyl, tert-butyl. “Lower alkyl” refers to an alkyl group having 1 to about 8 carbon atoms (i.e., a C1-8 alkyl), e.g., 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. “Higher alkyl” refers to an alkyl group having about 10 to about 20 carbon atoms, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. In certain embodiments, “alkyl” refers, in particular, to C1-5 straight-chain alkyls. In other embodiments, “alkyl” refers, in particular, to C1-5 branched-chain alkyls.
Alkyl groups can optionally be substituted (a “substituted alkyl”) with one or more alkyl group substituents, which can be the same or different. The term “alkyl group substituent” includes but is not limited to alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl. There can be optionally inserted along the alkyl chain one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms, wherein the nitrogen substituent is hydrogen, lower alkyl (also referred to herein as “alkylaminoalkyl”), or aryl.
Thus, as used herein, the term “substituted alkyl” includes alkyl groups, as defined herein, in which one or more atoms or functional groups of the alkyl group are replaced with another atom or functional group, including for example, alkyl, substituted alkyl, halogen, aryl, substituted aryl, alkoxyl, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate, and mercapto.
The term “aryl” is used herein to refer to an aromatic substituent that can be a single aromatic ring, or multiple aromatic rings that are fused together, linked covalently, or linked to a common group, such as, but not limited to, a methylene or ethylene moiety. The common linking group also can be a carbonyl, as in benzophenone, or oxygen, as in diphenylether, or nitrogen, as in diphenylamine. The term “aryl” specifically encompasses heterocyclic aromatic compounds. The aromatic ring(s) can comprise phenyl, naphthyl, biphenyl, diphenylether, diphenylamine and benzophenone, among others. In particular embodiments, the term “aryl” means a cyclic aromatic comprising about 5 to about 10 carbon atoms, e.g., 5, 6, 7, 8, 9, or 10 carbon atoms, and including 5- and 6-membered hydrocarbon and heterocyclic aromatic rings.
The aryl group can be optionally substituted (a “substituted aryl”) with one or more aryl group substituents, which can be the same or different, wherein “aryl group substituent” includes alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, hydroxyl, alkoxyl, aryloxyl, aralkyloxyl, carboxyl, acyl, halo, nitro, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acyloxyl, acylamino, aroylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylthio, alkylthio, alkylene, and —NR1R″, wherein R1 and R″ can each be independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, and aralkyl.
Thus, as used herein, the term “substituted aryl” includes aryl groups, as defined herein, in which one or more atoms or functional groups of the aryl group are replaced with another atom or functional group, including for example, alkyl, substituted alkyl, halogen, aryl, substituted aryl, alkoxyl, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate, and mercapto. Specific examples of aryl groups include, but are not limited to, cyclopentadienyl, phenyl, furan, thiophene, pyrrole, pyran, pyridine, imidazole, benzimidazole, isothiazole, isoxazole, pyrazole, pyrazine, triazine, pyrimidine, quinoline, isoquinoline, indole, carbazole, and the like.
“Cyclic” and “cycloalkyl” refer to a non-aromatic mono- or multicyclic ring system of about 3 to about 10 carbon atoms, e.g., 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. The cycloalkyl group can be optionally partially unsaturated. The cycloalkyl group also can be optionally substituted with an alkyl group substituent as defined herein, oxo, and/or alkylene. There can be optionally inserted along the cyclic alkyl chain one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms, wherein the nitrogen substituent is hydrogen, alkyl, substituted alkyl, aryl, or substituted aryl, thus providing a heterocyclic group. Representative monocyclic cycloalkyl rings include cyclopentyl, cyclohexyl, and cycloheptyl. Multicyclic cycloalkyl rings include adamantyl, octahydronaphthyl, decalin, camphor, camphane, and noradamantyl.
“Alkoxyl” refers to an alkyl-O— group wherein alkyl is as previously described. The term “alkoxyl” as used herein can refer to, for example, methoxyl, ethoxyl, propoxyl, isopropoxyl, butoxyl, f-butoxyl, and pentoxyl. The term “oxyalkyl” can be used interchangeably with “alkoxyl”. In some embodiments, the alkoxyl has 1, 2, 3, 4, or 5 carbons.
“Aralkyl” refers to an aryl-alkyl group wherein aryl and alkyl are as previously described, and included substituted aryl and substituted alkyl. Exemplary aralkyl groups include benzyl, phenylethyl, and naphthylmethyl.
“Alkylene” refers to a straight or branched bivalent aliphatic hydrocarbon group having from 1 to about 20 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. The alkylene group can be straight, branched or cyclic. The alkylene group also can be optionally unsaturated and/or substituted with one or more “alkyl group substituents.” There can be optionally inserted along the alkylene group one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms (also referred to herein as “alkylaminoalkyl”), wherein the nitrogen substituent is alkyl as previously described. Exemplary alkylene groups include methylene (—CH2—); ethylene (—CH2—CH2—); propylene (—(CH2)3—); cyclohexylene (—C6H10—); —CH═CH—CH═CH—; —CH═CH—CH2—; wherein each of q and r is independently an integer from 0 to about 20, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, and R is hydrogen or lower alkyl; methylenedioxyl (—O—CH2—O—); and ethylenedioxyl (—O—(CH2)2—O—). An alkylene group can have about 2 to about 3 carbon atoms and can further have 6-20 carbons.
“Arylene” refers to a bivalent aryl group. An exemplary arylene is phenylene, which can have ring carbon atoms available for bonding in ortho, meta, or para positions with regard to each other, i.e., respectively. The arylene group can also be napthylene. The arylene group can be optionally substituted (a “substituted arylene”) with one or more “aryl group substituents” as defined herein, which can be the same or different.
“Aralkylene” refers to a bivalent group that contains both alkyl and aryl groups. For example, aralkylene groups can have two alkyl groups and an aryl group (i.e., -alkyl-aryl-alkyl-), one alkyl group and one aryl group (i.e., -alkyl-aryl-) or two aryl groups and one alkyl group (i.e., -aryl-alkyl-aryl-).
The term “amino” and “amine” refer to nitrogen-containing groups such as NR3, NH3, NHR2, and NH2R, wherein R can be alkyl, branched alkyl, cycloalkyl, aryl, alkylene, arylene, aralkylene. Thus, “amino” as used herein can refer to a primary amine, a secondary amine, or a tertiary amine. In some embodiments, one R of an amino group can be a cation stabilized diazeniumdiolate (i.e., NONO−X+).
The terms “cationic amine” and “quaternary amine” refer to an amino group having an additional (i.e., a fourth) group, for example a hydrogen or an alkyl group bonded to the nitrogen. Thus, cationic and quaternary amines carry a positive charge.
The term “alkylamine” refers to the -alkyl-NH2 group.
The term “carbonyl” refers to the —(C═O)— group.
The term “carboxyl” refers to the —COOH group and the term “carboxylate” refers to an anion formed from a carboxyl group, i.e., —COO−.
The terms “halo”, “halide”, or “halogen” as used herein refer to fluoro, chloro, bromo, and iodo groups.
The term “hydroxyl” and “hydroxy” refer to the —OH group.
The term “hydroxyalkyl” refers to an alkyl group substituted with an —OH group.
The term “mercapto” or “thio” refers to the —SH group. The term “silyl” refers to groups comprising silicon atoms (Si).
As used herein the term “alkoxysilane” refers to a compound comprising one, two, three, or four alkoxy groups bonded to a silicon atom. For example, tetraalkoxysilane refers to Si(OR)4, wherein R is alkyl. Each alkyl group can be the same or different. An “alkylsilane” refers to an alkoxysilane wherein one or more of the alkoxy groups has been replaced with an alkyl group. Thus, an alkylsilane comprises at least one alkyl-Si bond. The term “fluorinated silane” refers to an alkylsilane wherein one of the alkyl groups is substituted with one or more fluorine atoms. The term “cationic or anionic silane” refers to an alkylsilane wherein one of the alkyl groups is further substituted with an alkyl substituent that has a positive (i.e., cationic) or a negative (i.e. anionic) charge, or can become charged (i.e., is ionizable) in a particular environment (i.e., in vivo).
The term “silanol” refers to a Si—OH group.
Provided according to some embodiments of the invention are topical medicaments that include NO-releasing macromolecules. In some embodiments, the NO-releasing macromolecules are diazeniumdiolate-functionalized polysiloxane macromolecules. Furthermore, in some embodiments, the medicaments include diazeniumdiolate-functionalized polysiloxane macromolecules in a gel.
In some embodiments of the invention, the properties of the gel are selected based on the properties of the diazeniumdiolate-functionalized polysiloxane macromolecules and the indication for which the topical gel is to be used, such that the interaction of the properties of the gel, macromolecule and skin environment act to provide the desired NO release profile. At the same time, the gel must be suitably stable and resist decomposition prior to topical application.
The Diazeniumdiolate-Functionalized Polysiloxane Macromolecules
The term “diazeniumdiolate-functionalized polysiloxane macromolecules” refers co-condensed polysiloxane macromolecules functionalized with diazeniumdiolate, such as the NO-releasing particles described in U.S. Publication No. 2009/0214618, the disclosure of which is incorporated by reference herein in its entirety. Such particles may be prepared by methods described therein.
In some embodiments, the nitric oxide donor may be formed from an aminoalkoxysilane by a pre-charging method, and the co-condensed siloxane network may be synthesized from the condensation of a silane mixture that includes an alkoxysilane and the aminoalkoxysilane to form a nitric oxide donor modified co-condensed siloxane network. As used herein, the “pre-charging method” means that aminoalkoxysilane is “pretreated” or “precharged” with nitric oxide prior to the co-condensation with alkoxysilane. In some embodiments, the precharging nitric oxide may be accomplished by chemical methods. In another embodiment, the “pre-charging” method can be used to create co-condensed siloxane networks and materials more densely functionalized with NO-donors.
The co-condensed siloxane network can be silica particles with a uniform size, a collection of silica particles with a variety of size, amorphous silica, a fumed silica, a nanocrystalline silica, ceramic silica, colloidal silica, a silica coating, a silica film, organically modified silica, mesoporous silica, silica gel, bioactive glass, or any suitable form or state of silica.
In some embodiments, the alkoxysilane is a tetraalkoxysilane having the formula Si(OR)4, wherein R is an alkyl group. The R groups can be the same or different. In some embodiments the tetraalkoxysilane is selected as tetramethyl orthosilicate (TMOS) or tetraethyl orthosilicate (TEOS). In some embodiments, the aminoalkoxysilane has the formula: R″—(NH—R′)n—Si(OR)3, wherein R is alkyl, R′ is alkylene, branched alkylene, or aralkylene, n is 1 or 2, and R″ is selected from the group consisting of alkyl, cycloalkyl, aryl, and alkylamine.
In some embodiments, the aminoalkoxysilane can be selected from N-(6-aminohexyl)aminopropyltrimethoxysilane (AHAP3); N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (AEAP3); (3-trimethoxysilylpropyl)di-ethylenetriamine (DET3); (amino ethylaminomethyl)phenethyltrimethoxysilane (AEMP3); [3-(methylamino)propyl]trimethoxysilane (MAP3); N-butylamino-propyltrimethoxysilane(n-BAP3); t-butylamino-propyltrimethoxysilane(t-BAP3); N-ethylaminoisobutyltrimethoxysilane(EAiB3); N-phenylamino-propyltrimethoxysilane (PAP3); and N-cyclohexylaminopropyltrimethoxysilane (cHAP3).
In some embodiments, the aminoalkoxysilane has the formula: NH [R′—Si(OR)3]2, wherein R is alkyl and R′ is alkylene. In some embodiments, the aminoalkoxysilane can be selected from bis(3-triethoxysilylpropyl)amine, bis-[3-(trimethoxysilyl)propyl]amine and bis-[(3-trimethoxysilyl)propyl]ethylenediamine.
In some embodiments, as described herein above, the aminoalkoxysilane is precharged for NO-release and the amino group is substituted by a diazeniumdiolate. Therefore, in some embodiments, the aminoalkoxysilane has the formula: R″—N(NONO−X+)—R′—Si(OR)3, wherein R is alkyl or silyl, R′ is alkylene or aralkylene, R″ is alkyl or alkylamine, and X+ is a cation selected from the group consisting of Na+, K+, Cs+, Li+, NH4+, or other quaternary ammonium cation.
In some embodiments of the invention, the diazeniumdiolate-functional aminoalkoxysilane may be O2-protected prior to the preparation of the nitric oxide releasing macromolecules. Such O2-protected diazeniumdiolate functional aminoalkoxysilanes may have the formula: R″—N(NONO—R′″)—X—Si(OR)3, wherein each R is independently H, alkyl or substituted alkyl, R′ is substituted or unsubstituted alkylene, substituted or unsubstituted arylene, substituted or unsubstituted alkylarylene or substituted or unsubstituted arylalkylene, R″ is H, alkyl or substituted alkyl and R′″ is a protecting group that imparts enzymatic, photolytic, or thiolation triggering mechanisms. Such protecting groups are known to those skilled in the art of forming O2-protected diazeniumdiolates.
The chemical composition of the siloxane network, (e.g., amount or the chemical composition of the aminoalkoxysilane), the porosity of the silica network within the macromolecular structure, the size of the co-condensed silica particles, and the nitric oxide charging conditions (e.g., the solvent and base) can be varied to optimize the amount and duration of nitric oxide release. Thus, in some embodiments, the composition of the silica particles can be modified to regulate the half-life of NO release from silica particles with half-lives of nitric oxide release ranging from slow, defined by t1/2 values greater than 60 minutes to fast, defined by t1/2 values ranging from 30 seconds to 10 minutes.
In some embodiments of the invention, the co-condensed siloxane network of nitric oxide releasing silica particles is formed from at least one additional silane that modifies surface charge and/or hydrophilicity/hydrophobicity of the co-condensed silica product which affect the octanol/water partition coefficient of the macromolecular delivery vehicle. These parameters control the route of skin penetration, depth of penetration, and diffusion of the diazeniumdiolate-modified polysiloxane macromolecules out of topical gel vehicles. Any suitable alkoxysilane that may impart surface charge to the diazeniumdiolate-modified polysiloxane macromolecule may be used. Thus, in some embodiments, the additional alkoxysilane may include a cationic alkoxysilane such as (2-N-benyzlaminoethyl)-3-aminopropyl-trimethoxysilane, hydrocholoride; bis(methoxyethyl)-3-trimethoxysilylpropyl-ammonium chloride; N—N-didecyl-N-methyl-N-(3-trimethoxysilyl)ammonium chloride; N-trimethyoxysilylpropyl-N,N,N-trimethyl ammonium chloride; octadecylbis(triethoxysilylpropyl)-ammonium chloride; and octadecyldimethyl(3-trimethoxysilylpropyl)ammonium chloride. In some embodiments, the additional alkoxysilane may include an anionic alkoxysilanes such as 3-trihydroxysilylpropylmethyl phosphonate, sodium salt and carboxyethylsilanetriol, sodium salt.
Any suitable alkoxysilane that may impart hydrophilic properties to the diazeniumdiolate-modified polysiloxane macromolecule may be used. Alkoxysilanes containing repeat poly(ethylene)oxy groups may be used to increase the wetability of the NO-releasing particles thereby helping to improve biocompatibility upon topical application and also enhance the rate of water uptake into the co-condensed siloxane coating. Surface hydrophilicity can thus be utilized to enhance the NO-release kinetics of the diazeniumdiolated aminoalkoxysilane derivatives. Therefore, in some embodiments, the multifunctional alkoxysilane may include a hydrophilic silane such as N-triethoxysilylpropyl)-O-polyethyleneoxide urethane; N-3-[amino(polypropylenoxy)]aminopropyltrimethoxysilane; bis-[3-(triethoxysilylpropoxy)-2-hydroxypropoxy]polyethylene oxide; bis(3-triethoxysilylpropyl)polyethylene oxide (25-30); [hydroxy(polyethyleneoxy)propyl]-triethoxysilane; and 2-[methoxy(polyethyleneoxy)propyl]-trimethoxysilane.
Any suitable alkoxysilane that may impart hydrophobic properties to the diazeniumdiolate-modified polysiloxane macromolecule may be used. Hydrophobic silanes are known to those skilled in the art to increase lipophilicity of particle surfaces. In some embodiments, the additional alkoxysilane may include linear alkyl, branched and cyclic alkylalkoxysilanes having at least three carbon atoms, substituted and unsubstituted phenyl alkoxysilanes, and fluorinated alkoxysilanes. Exemplary fluoroalkoxysilanes may include heptadecafluoro-1,1,2-2-tetrahydrodecyl)triethoxysilane (shown in
The hydrophilicity of the diazeniumdiolate-functionalized polysiloxane macromolecules can be assessed by the use of a water/octanol partition coefficient. See Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry, Vol. 2 of Wiley Series in Solution Chemistry. Chichester: John Wiley & Sons Ltd. (1997), which is herein incorporated by reference in its entirety. For example, hydrophobic diazeniumdiolate-functionalized polysiloxane macromolecules may have a water/octanol partition coefficient in a range of 0.1 to 7, and hydrophilic diazeniumdiolate-functionalized polysiloxane macromolecules may have a water/octanol partition coefficient in a range of −2 to 0.
In some embodiments of the invention, the hydrodynamic radius of the NO-releasing macromolecule is within a range of 1 nm to 100 nm, which may maximize trans-epidermal skin penetration and enhance nitric oxide delivery to deeper skin structures or, the size of the macromolecular scaffold may be selected to be in a range of 101 nm to 1000 nm to selectively accumulate diazeniumdiolate-modified polysiloxane macromolecules in the stratum corneum and limit skin penetration, systemic absorption, and any resulting toxicity of the macromolecular scaffold, or the size of the macromolecule scaffold may be selected to be in a range of 1000 nm to 10,000 nm to target skin penetration via the trans-follicular route. Selective delivery to the stratum corneum, epidermis or dermis may be achieved by varying the particle size. Skin naturally has a low permeability to particulate materials and the stratum corneum provides an effective barrier to most inorganic nanosized particles with gold nanoparticles, silver nanoparticles, quantum dots, titanium dioxodie, and zinc oxide being the most extensively studied. See, e.g., Baroli, B., Penetration of Nanoparticles and Nanomaterials in the Skin: Fiction or Reality? Journal of Pharmaceutical Sciences, 2009 December; 99:21-50. Despite the current understanding of one skilled in the art of skin penetration, the skin penetration of silica particles as a function of size is poorly understood.
The diazeniumdiolate-functionalized polysiloxane macromolecules may be present in medicaments according to embodiments of the invention at any suitable concentration, but in some embodiments, the diazeniumdiolate-functionalized polysiloxane macromolecules are present in the medicaments at a concentration sufficient to increase the rate of wound healing, decrease inflammation and/or exert an antimicrobial effect. In particular embodiments, the concentration of diazeniumdiolate-functionalized polysiloxane macromolecules is in a range of 0.01 percent to 20 percent w/w. In some embodiments, the concentration of the diazeniumdiolate-functionalized polysiloxane macromolecules in the medicament may be adjusted to modulate the amplitude of nitric oxide release (mol NO/g medicament) either by changing the weight percentage in the gel or by varying the loading of nitric oxide on the macromolecular scaffold to create a desirable therapeutic outcome.
In some embodiments, to prevent platelet activation and aggregation, the final NO storage per gram of gel may be in a range of 0.1 pmol NO/g gel to 100 nmol/g gel. In some embodiments, to reduce inflammation and associated inflammatory response factors, the final NO storage per gram of gel may be in a range of 100 pmol NO/g gel to 1 umol NO/g gel. In some embodiments, to promote wound healing, the final NO storage per gram of gel may be in a range of 1 nmol NO/g gel to 10 μmol NO/g gel. In some embodiments, to exert antimicrobial activity, the final NO storage per gram of gel may be in a range of 10 μmol NO/g gel to 1 mmol NO/g gel. In some embodiments, to treat biofilms by dispersal, the final NO storage per gram of gel may be in a range of 10 nmol NO/g gel to 1 μmol NO/g gel, and in some embodiments, to treat biofilms by direct microbicidal activity, the final NO storage per gram of gel may be in a range of 100 μmol NO/g gel to 1 mmol NO/g gel.
Topical Gels
The properties of the topical gels, including the NO-release profile, may be tailored by the selection of the gel composition. The gels may also provide beneficial or therapeutic action to the skin or wound bed (e.g., moisturize, absorb wound exudate, provide an occlusive barrier, etc.) that may directly affect skin conditions or wound healing. The excipients that form the gels may also indirectly affect wound healing by affecting the stability of the diazeniumdiolate-functionalized polysilane macromolecules or other therapeutic agents within the medicament and/or controlling the rates of decomposition of the NO donors to generate nitric oxide. The intrinsic pH of the topical gel can be elevated to between 8 and 10 to maintain NO donor stability and react with the acid mantle on the surface of the skin to neutralize pH and initiate decomposition of diazeniumdiolate nitric oxide donors.
Excipients for use in topical gels are well-known in the art and examples may be found in the Handbook of Pharmaceutical Excipients (Rowe, R. C. et al., APhA Publications; 5th ed., 2005). Exemplary excipients may include waxes, various sugars and types of starch, polymers, gels, emollients, thickening agents, rheology modifiers, humectants, glycerol, organic basic compounds, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and solvents. Examples of rheology modifiers include Carbopol, hydroxypropyl cellulose, C26-28 alkyl dimethicone, C26-28 alkyl methicone, polyphenylsisquioxane, trimethylsiloxysilicate, crosspolymers of cyclopentasiloxane and dimethicone/vinyltrimethylsiloxysilicate, fumed silica (e.g. Cab-O-Sil M5P), and mixtures thereof. Examples of emollients include glycerine, pentylene glycol, sodium pyrrolidone carboxylic acid, lanolin, saccharide isomerate, stearoxy dimethicone, stearyl dimethicone, and mixtures thereof. Emollients may be useful to prevent stratum corneum dehydration occurring due to the use of anhydrous solvents in the formulation. Examples of organic bases include 2-amino-2-methyl propanol, niacinamide, methanolamines, triethanolamines, Trisamino, AMP-95, AmP-Ultra PC 2000, triisopropanolamine, diisopropanolamine, Neutrol TE, Ethomeen, and mixtures thereof. The organic base may render the pH of the medicament basic or neutral, and may directly affect the release of NO from the diazeniumdiolate groups by slowing donor decomposition with increasing alkalinity.
Other exemplary excipients include water-soluble porogens. A water-soluble porogen is an additive that may facilitate water uptake and diffusion into the gel. Any suitable porogen may be used, but in some embodiments, the porogen may include sodium chloride, potassium chloride, sucrose, glucose, lactose, sorbitol, xylitol, polyethylene glycol, polyvinylpyrrollidone, polyvinyl alcohol or mixtures thereof. Electrolytes, like KCl, may also be added as excipients to enhance the stability of diazeniumdiolate NO donors.
Polymers may also act as excipients in topical gels. Exemplary polymers include hydrophilic polyurethanes, hydrophilic polyacrylates, co-polymers of carboxymethylcellulose and acrylic acid, N-vinylpyrrolidone, poly(hydroxy acids), polyanhydrides, polyorthoesters, polyamides, polycarbonates, polyalkylenes (e.g., polyethylene and polypropylene), polyalkylene glycols (e.g., poly(ethylene glycol)), polyalkylene oxides (e.g., polyethylene oxide), polyalkylene terephthalates (e.g., polyethylene terephthalate), polyvinyl alcohols, polyvinyl ethers, polylvinyl esters, polyvinyl halides (e.g., poly(vinyl chloride)), polyvinylpyrrolidone, polysiloxanes, poly(vinyl acetates), polystyrenes, polyurethane copolymers, cellulose, derivatized celluloses, alginates, poly(acrylic acid), poly(acrylic acid) derivatives, acrylic acid copolymers, methacrylic acid, methacrylic acid derivatives, methacrylic acid copolymers, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), copolymers thereof and blends thereof.
In some embodiments of the invention, the polymers may be superabsorbent polymers (SAPs). A polymer is considered superabsorbent, as defined per IUPAC, as a polymer that can absorb and retain extremely large amounts of water relative to its own mass. SAPs may absorb water up to 500 times their own weight and may swell up to 1000-times their original volume. Particular SAPs of interest include sodium polyacrylate, the polyurethane Tecophilic TG-2000, and polymers prepared by the use of polyacrylamide copolymer, ethylene maleic anhydride copolymer, cross-linked carboxy-methyl-cellulose, polyvinyl alcohol copolymers, polyvinylpyrrolindone and cross-linked polyethylene oxide. In some embodiments, the SAP may absorb water from the wound bed, thereby causing NO to release from the diazeniumdiolate-functionalized polysilane macromolecules.
In some embodiments of the invention, polymers that are relatively hydrophobic may be used. Any suitable hydrophobic polymer may be used. However, exemplary polymers that are relatively hydrophobic include aromatic polyurethanes, silicone rubber, polysiloxanes, polycaprolactone, polycarbonate, polyvinylchloride, polyethylene, poly-L-lactide, poly-DL-glycolide, polyetheretherketone (PEEK), polyamide, polyimide and polyvinyl acetate. In addition, a hydrophobic gel-base and/or rheology modifier may be used.
In some embodiments of the invention, the polymers may act as thickening agents in the medicaments. Specifically, the polymeric portion of the gel may act as a visco-elastic substance and may retain the gel at the site of application, along with the diazeniumdiolate-functionalized polysilane macromolecules dispersed therein.
In some other embodiments, a gel that includes a polymer may have spreadability such that it forms a thin film when applied on the skin surface. This film may enable the application of the contained NO-releasing polysiloxane macromolecules over a wide area, and may serve to maintain the NO-releasing polysiloxane macromolecules on the affected area of the skin.
Other excipients may include various ionic or non-ionic compounds to maintain stability of the formulation, thereby protecting from the de-emulsification, settling, agglomeration or degradation of the formulation constituents that may reduce its therapeutic or aesthetic value.
Examples of ionic compounds may include salts such as sodium chloride, potassium chloride; cationic, anionic or zwitterionic surfactants such as sodium dodecyl sulfate (SDS), perfluorooctanoate (PFOA), perfluorooctanesulfonate (PFOS), ammonium lauryl sulfate (ALS), sodium lauryl ether sulfate (SLES), alkyl benzene sulfonate, cetyl trimethylammonium bromide (CTAB), cetylpyridinium chloride (CPC), polyethoxylated tallow amine (POEA), benzalkonium chloride (BAC), benzethonium chloride, dodecyl betaine, cocamidopropyl betaine and cocoamphoglycinate.
Examples of non-ionic compounds that may act as excipients include non-ionic surfactants such as Pluronic, Tween, AMP, and Brij family of surfactants; and surfactants derived from biological sources, e.g, natural or semi-synthetic surfactants, such as oleic acid, sorbitan trioleate, sorbitan monooleate, lecithin, cocamide MEA, cocamide DEA and cocamidopropyl betaine. Surfactants (both ionic and non-ionic) may reduce the interfacial surface energy and may facilitate spreading of the ointment or liquid over a wider area.
In some embodiments of the invention, solvent excipients may be used as a carrier vehicle for the NO-releasing macromolecules and other excipients. The polymer chains may interact with the solvent and undergo swelling to form a network that may impart visco-elastic properties to the medicament. In some embodiments of the medicament, the solvent may evaporate upon application, leaving a residual film of the polymer along with the entrapped NO-releasing macromolecules.
Exemplary solvent excipients that may be useful in hydrophilic formulations may include dimethyl isosorbide, propylene glycol, glycerol, isopropanol, ethanol, benzyl alcohol, ethylene glycol, polyethylene glycol, ethoxydiglycol or mixtures thereof. Exemplary solvent excipients that may be useful in hydrophobic formulations may include capric/caprylic triglycerides, isopropyl myristate, mineral oil, isododecane, isodecyl neopentanoate, butylene glycol, pentylene glycol, hexylene glycol, methoxypolyethyleneglycol, cyclopentasiloxane, cyclotetrasiloxane, dimethicone, caprylyl methicone or mixtures thereof. In some embodiments, the hydrophilic gel may be an alcoholic gel, wherein the gel has an alcohol content in a range of 20 to 90 weight percent, and in some cases, in a range of 60 to 85 weight percent.
In addition to the diazeniumdiolate-functionalized polysiloxane macromolecules and excipients, the topical gels may also include at least one additional therapeutic agent such as antimicrobial agents, anti-acne agents, anti-inflammatory agents, analgesic agents, anesthetic agents, antihistamine agents, antiseptic agents, immunosuppressants, antihemorrhagic agents, vasodilators, wound healing agents, anti-biofilm agents and mixtures thereof.
Examples of antimicrobial agents include penicillins and related drugs, carbapenems, cephalosporins and related drugs, erythromycin, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomysin, tetracyclines, vanomycin, teicoplanin, streptogramins, anti-folate agents including sulfonamides, trimethoprim and its combinations and pyrimethamine, synthetic antibacterials including nitrofurans, methenamine mandelate and methenamine hippurate, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, viomycin, eveminomycin, glycopeptide, glyclyclycline, ketolides, oxazolidinone; imipenen, amikacin, netilmicin, fosfomycin, gentamycin, ceftriaxone, Ziracin, Linezolid, Synercid, Aztreonam, and Metronidazole, Epiroprim, Sanfetrinem sodium, Biapenem, Dynemicin, Cefluprenam, Cefoselis, Sanfetrinem celexetil, Cefpirome, Mersacidin, Rifalazil, Kosan, Lenapenem, Veneprim, Sulopenem, ritipenam acoxyl, Cyclothialidine, micacocidin A, carumonam, Cefozopran and Cefetamet pivoxil.
Examples of topical anti-acne agents include adapalene, azelaic acid, benzoyl peroxide, clindamycin and clindamycin phosphate, doxycycline, erythromycin, keratolytics such as salicylic acid and retinoic acid (Retin-A″), norgestimate, organic peroxides, retinoids such as isotretinoin and tretinoin, sulfacetamide sodium, and tazarotene. Particular anti-acne agents include adapalene, azelaic acid, benzoyl peroxide, clindamycin (e.g., clindamycin phosphate), doxycycline (e.g., doxycycline monohydrate), erythromycin, isotretinoin, norgestimate, sulfacetamide sodium, tazarotene, etretinate and acetretin.
Examples of antihistamine agents include diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine, chlorpheniramine hydrochloride, chlorpheniramine maleate isothipendyl hydrochloride, tripelennamine hydrochloride, promethazine hydrochloride, methdilazine hydrochloride, and the like. Examples of local anesthetic agents include dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, benzocaine, p-buthylaminobenzoic acid 2-(die-ethylamino) ethyl ester hydrochloride, procaine hydrochloride, tetracaine, tetracaine hydrochloride, chloroprocaine hydrochloride, oxyprocaine hydrochloride, mepivacaine, cocaine hydrochloride, piperocaine hydrochloride, dyclonine and dyclonine hydrochloride.
Examples of antiseptic agents include alcohols, quaternary ammonium compounds, boric acid, chlorhexidine and chlorhexidine derivatives, iodine, phenols, terpenes, bactericides, disinfectants including thimerosal, phenol, thymol, benzalkonium chloride, benzethonium chloride, chlorhexidine, povidone iode, cetylpyridinium chloride, eugenol and trimethylammonium bromide.
Examples of anti-inflammatory agents include nonsteroidal anti-inflammatory agents (NSAIDs); propionic acid derivatives such as ibuprofen and naproxen; acetic acid derivatives such as indomethacin; enolic acid derivatives such as meloxicam, acetaminophen; methyl salicylate; monoglycol salicylate; aspirin; mefenamic acid; flufenamic acid; indomethacin; diclofenac; alclofenac; diclofenac sodium; ibuprofen; ketoprofen; naproxen; pranoprofen; fenoprofen; sulindac; fenclofenac; clidanac; flurbiprofen; fentiazac; bufexamac; piroxicam; phenylbutazone; oxyphenbutazone; clofezone; pentazocine; mepirizole; tiaramide hydrochloride; steroids such as clobetasol propionate, bethamethasone dipropionate, halbetasol proprionate, diflorasone diacetate, fluocinonide, halcinonide, amcinonide, desoximetasone, triamcinolone acetonide, mometasone furoate, fluticasone proprionate, betamethasone diproprionate, triamcinolone acetonide, fluticasone propionate, desonide, fluocinolone acetonide, hydrocortisone vlaerate, prednicarbate, triamcinolone acetonide, fluocinolone acetonide, hydrocortisone and others known in the art, predonisolone, dexamethasone, fluocinolone acetonide, hydrocortisone acetate, predonisolone acetate, methylpredonisolone, dexamethasone acetate, betamethasone, betamethasone valerate, flumetasone, fluorometholone, beclomethasone diproprionate, fluocinonide, topical corticosteroids, and may be one of the lower potency corticosteroids such as hydrocortisone, hydrocortisone-21-monoesters (e.g., hydrocortisone-21-acetate, hydrocortisone-21-butyrate, hydrocortisone-21-propionate, hydrocortisone-21-valerate, etc.), hydrocortisone-17,21-diesters (e.g., hydrocortisone-17,21-diacetate, hydrocortisone-17-acetate-21-butyrate, hydrocortisone-17,21-dibutyrate, etc.), alclometasone, dexamethasone, flumethasone, prednisolone, or methylprednisolone, or may be a higher potency corticosteroid such as clobetasol propionate, betamethasone benzoate, betamethasone dipropionate, diflorasone diacetate, fluocinonide, mometasone furoate, triamcinolone acetonide.
Examples of analgesic agents include alfentanil, benzocaine, buprenorphine, butorphanol, butamben, capsaicin, clonidine, codeine, dibucaine, enkephalin, fentanyl, hydrocodone, hydromorphone, indomethacin, lidocaine, levorphanol, meperidine, methadone, morphine, nicomorphine, opium, oxybuprocaine, oxycodone, oxymorphone, pentazocine, pramoxine, proparacaine, propoxyphene, proxymetacaine, sufentanil, tetracaine and tramadol.
Examples of anesthetic agents include alcohols such as phenol; benzyl benzoate; calamine; chloroxylenol; dyclonine; ketamine; menthol; pramoxine; resorcinol; troclosan; procaine drugs such as benzocaine, bupivacaine, chloroprocaine; cinchocaine; cocaine; dexivacaine; diamocaine; dibucaine; etidocaine; hexylcaine; levobupivacaine; lidocaine; mepivacaine; oxethazaine; prilocaine; procaine; proparacaine; propoxycaine; pyrrocaine; risocaine; rodocaine; ropivacaine; tetracaine; and derivatives, such as pharmaceutically acceptable salts and esters including bupivacaine HCl, chloroprocaine HCl, diamocaine cyclamate, dibucaine HCl, dyclonine HCl, etidocaine HCl, levobupivacaine HCl, lidocaine HCl, mepivacaine HCl, pramoxine HCl, prilocaine HCl, procaine HCl, proparacaine HCl, propoxycaine HCl, ropivacaine HCl, and tetracaine HCl.
Examples of antihemorrhagic agents include thrombin, phytonadione, protamine sulfate, aminocaproic acid, tranexamic acid, carbazochrome, carbaxochrome sodium sulfanate, rutin and hesperidin.
In addition to the diazeniumdiolate-functionalized polysiloxane macromolecules, excipients, and other therapeutic agents, the gels may also include other compounds that improve the organoleptic properties of the medicament. Examples of such compounds include perfumes, dyes and colorants; chelating agents including but not limited to EDTA, EGTA, CP94, citric acid; preservatives including but not limited to quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetrimide, dequalinium chloride, and cetylpyridinium chloride; mercurial agents, such as phenylmercuric nitrate, phenylmercuric acetate, and thimerosal; alcoholic agents, for example, chlorobutanol, phenylethyl alcohol, and benzyl alcohol; antibacterial esters, for example, esters of parahydroxybenzoic acid; and other anti-microbial agents such as chlorhexidine, chlorocresol, benzoic acid and polymyxin.
Tailoring Gels for Particular Therapeutic Uses
Wound healing occurs in several different phases, and may take place over 0-12 (or more) months. Wound healing phases include:
(i) Clotting
(ii) Cell Proliferation
(iii) Granulation Tissue Formation
(iv) Epithelialization
(v) Neovascularization or angiogenesis
(vi) Wound Contraction
(vii) Matrix deposition including collagen synthesis
(viii) Tissue Remodeling, including scar formation and scar remodeling
Nitric oxide may play a role in wound healing by a number of different mechanisms. First, extended exposure to low concentrations of nitric oxide may promote wound healing whereby nitric oxide acts as a signaling molecule in a number of wound healing cascades. Additionally, nitric oxide may also play a role in mitigating inflammation following injury. Modulation of inflammatory cytokines and cells of the inflammatory response via nitric oxide may significantly alter the wound healing phases above. Additionally, wound complications and pain may be significantly reduced with topical administration of nitric oxide as an anti-inflammatory agent. Furthermore, nitric oxide may act as a broad spectrum antimicrobial agent, particularly at relatively high concentrations. The antimicrobial effects of nitric oxide are broad ranging and different wound types may be colonized with different wound pathogens (e.g., gram negative bacteria, gram positive bacteria, fungus, etc.). Additionally, some pathogens may be more sensitive to nitric oxide than other pathogens. In some embodiments, nitric oxide may act as an antimicrobial agent by directly killing planktonic bacteria and other organisms; directly killing biofilm embedded bacteria and other organisms; indirectly killing microorganisms through nitrosative/oxidative stress; loosening biofilm matrix; increasing drug permeability across microbial membranes; and/or preventing recurrence of infection or biofilm formation.
Therefore, in some embodiments, the nitric oxide released from a particular medicament may provide a particular therapeutic action, such as act as a signaling molecule in a wound healing cascade, act as an anti-inflammatory agent and/or act as an antimicrobial agent. As such, the particular diazeniumdiolate-functionalized polysiloxane macromolecules and the composition of the gel may be tailored to provide the appropriate NO-release profile. Diazeniumdiolates may be triggered to release nitric oxide by exposure to water or another proton source, and an O2-protected diazeniumdiolate may be triggered to release nitric oxide by exposure to light, enzymatic action and/or pH adjustment.
Properties that may be tuned via the pharmaceutically acceptable carrier chosen include hydrophilicity and water uptake. The equilibrium moisture retention for a polymer can vary from 5 percent for certain aliphatic polymers to over 2000 percent for hydrogels and superabsorbent polymers. Thus, in some embodiments, the medicament may include a polymer that has a low equilibrium moisture retention in a range of less than 1 percent to 20 percent. In some embodiments, the medicament may include a polymer that has a moderate equilibrium moisture retention in a range of 20 percent to 200 percent. Further, in some embodiments, the medicament may include a polymer that has a high equilibrium moisture retention of 200 percent or higher. Other excipients may also absorb water and/or be hydrophilic or hydrophobic. In some embodiments, the gel may also include highly water absorbent excipients (e.g., an SAP, a humectant and/or glycerol) if fast release of NO is desired. If slower release of NO is desired, the gel may be more hydrophobic.
For topical medicaments that are gels or include monomers that may form gels upon polymerization, the properties of the gel may be tailored to affect desired NO-release characteristics. Properties of the gel that may be tailored include:
(i) Moisture Vapor Transfer Rate (MVTR)
(ii) Biodegradability/Bioabsorbability
(iii) Oxygen Permeability
(iv) Nitric Oxide Permeability
(v) Ability to Swell
(vi) Biocompatibility
(vii) Ionic Character
In some embodiments of the invention, at least one property of the gel and/or at least one property of the diazeniumdiolate-functionalized polysiloxane macromolecules may affect the moisture uptake/retention, the moisture vapor transfer rate (MVTR), oxygen permeability, NO permeability, biodegradability/bioabsorbability, biocompatibility and ionic character. The total quantity of nitric oxide stored in the macromolecules, the hydrophobicity/hydrophilicity of the macromolecules and the gel, and the biodegradability/bioresorbability of the macromolecules and the gel control the intrinsic pH, the equilibrium moisture uptake, and regulate diffusion of oxygen into the gel to modulate nitrosative intermediates or the appearance of nitrite/nitrate byproducts. The formation of a polymer gel may also entrap diazeniumdiolate-functionalized polysiloxane macromolecules and prevent or minimize their penetration into the wound bed.
In some embodiments of the invention, the gel is a hydrophobic and non-aqueous gel. The use of an anhydrous and hydrophobic gel may minimize or prevent the release of NO during storage of the formulation. The hydrophic, non-aqueous compositions may also allow for slower diffusion of water required to initiate diazeniumdiolate decomposition and subsequent release of NO to a wound. As such, the gel may be useful for the treatment of acute and/or chronic wounds.
In some embodiments of the invention, the hydrophobic, non-aqueous gel base may be a silicone gel. In particular embodiments, the silicone gel includes cyclomethicone at a concentration in a range of 5 to 30 weight percent and crosslinked polydimethylsiloxane at a concentration in a range of 65 to 85 weight percent. In other embodiments, the hydrophobic, non-aqueous gel base includes polyol at a concentration in a range of 67 to 76 weight percent; electrolyte at a concentration in a range of 0.1 to 2.5 weight percent; silicone polyol at a concentration in a range of 20 to 30 weight percent; and volatile silicone-based solvent at a concentration in a range of 2.5 to 13 weight percent. In other embodiments, the hydrophobic, non-aqueous gel base includes petrolatum at a concentration in a range of 60 to 70 weight percent; dimethiconol at a concentration in a range of 5 to 10 weight percent; and volatile silicone-based solvent.
Further, in other embodiments, the hydrophobic, non-aqueous gel base includes a silicone elastomer at a concentration in a range of 60 to 70 weight percent; and volatile organic solvent at a concentration in a range of 5 to 10 weight percent, and in other embodiments, the hydrophobic, non-aqueous gel base includes silicone elastomer at a concentration in a range of 70 to 80 weight percent; and volatile organic solvent at a concentration in a range of 15 to 20 weight percent.
In addition, in some embodiments, the resulting hydrophobic, non-aqueous gel containing diazeniumdiolate-functionalized polysiloxane macromolecules may have a MVTR below 840 g/m2 per 24 hour period.
Any suitable polyol may be used in the compositions described herein. However, examples of polyols include 1,2-ethanediol, 1,3-propanediol, 1,4-butanediol, 1,6-hexanediol, 1,5-pentanediol, 1,10-decanediol, 2-methyl-1,3-propanediol, 2-methyl-2-butyl-1,3-propanediol, 2,2-dimethyl-1,3-propanediol, 2,2-dimethyl-1,4-butanediol, 2-ethyl-2-butyl-1,3-propanediol, neopentyl glycol hydroxypivalate, diethylene glycol and triethylene glycol.
Any suitable electrolyte may be used. However, examples of electrolytes include sodium chloride, potassium chloride, calcium chloride, and magnesium chloride.
Any suitable silicone polyol may be used. However examples of silicone polyols include dimethicone copolyol, laurylmethicone copolyol, cetyldimethicone copolyol, SilSense® SW-12 dimethicone copolyol ester, SilSense® Copolyol-1 Silicone, Lambent waxes, PEG/PPG-4/12 dimethicone, Bis-PEG/PPG-20/20 dimethicone, PEG/PPG-20/6 dimethicone, PEG/PPG-14/4 dimethicone, and PEG/PPG-20/20 dimethicone.
Any suitable silicone-based solvent may be used. However, examples of silicone-based solvents include cyclomethicone and dimethicone.
Any suitable silicone elastomer may be used. However, examples of silicone elastomers include dimethicone crosspolymer, dimethicone/vinyl dimethicone crosspolymer, cyclopentasiloxane/dimethicone crosspolymer, cetearyl/dimethicone crosspolymer, Wacker Belsil RG-100, ST-Elastomer 10, and trimethylsiloxysilicate/timethiconol crosspolymer.
In some embodiments, the gel includes diazeniumdiolate-functionalized polysiloxane macromolecules, caprylic or capric triglyceride at a concentration in a range of 25 to 55 weight percent; fumed silica at a concentration in a range of 4 to 8 weight percent; cyclomethicone at a concentration in a range of 5 to 20 weight percent; optionally, isopropyl myristate at a concentration in a range of 10 to 85 weight percent; and optionally, mineral oil at a concentration in a range of 10 to 90 weight percent.
In some embodiments, the topical gel includes diazeniumdiolate-functionalized polysiloxane macromolecules and a hydrophilic gel base. In particular embodiments, the concentration of the diazeniumdiolate-functionalized polysiloxane macromolecules is in a range of 0.1 to 2 weight percent. Further, in particular embodiments, the gel includes diazeniumdiolate-functionalized polysiloxane macromolecules, an ethylcellulose polymer at a concentration in a range of 8 to 20 weight percent; and a fatty acid ester at a concentration in a range of 60 to 90 weight percent.
In some embodiments, the gel includes diazeniumdiolate-functionalized polysiloxane macromolecules, polyethylene glycol at a concentration in a range of 15 to 60 weight percent; and propylene glycol at a concentration in a range of 30 to 80 weight percent; crosslinked polyacrylic acid at a concentration in a range of 0.5 to 4.0 weight percent; optionally, 2-amino-2-methyl propanol at a concentration in a range of 0.05 to 0.15 weight percent; optionally, glycerin at a concentration in a range of 15 to 25 weight percent; and optionally, niacinamide at a concentration in a range of 0.25 to 1.25 weight percent.
In some embodiments, the gel includes diazeniumdiolate-functionalized polysiloxane macromolecules, benzyl alcohol at a concentration in a range of 10 to 30 weight percent; isopropyl alcohol at a concentration in a range of 30 to 75 weight percent; HPC at a concentration in a range of 0.75 to 2.5 weight percent; optionally, 2-amino-2-methyl propanol at a concentration in a range of 0.05 to 0.15 weight percent; optionally, trolamine at a concentration in a range of 0.1 to 1.5 weight percent; optionally, fumed silica at a concentration in a range of 1.0 to 7.0 weight percent; and optionally, niacinamide at a concentration in a range of 0.25 to 1.25 weight percent.
In some embodiments of the invention, the diazeniumdiolate-functionalized polysiloxane macromolecules in the hydrophilic gel may have an octanol/water partition coefficient in a range of −2 to 0. In some embodiments of the invention, the diazeniumdiolate-functionalized polysiloxane macromolecules in the hydrophobic, non-aqueous gel may have an octanol/water partition coefficient in a range of 0.1 to 7.
Methods of Treating Wounds and Skin Ailments
In some embodiments of the invention, provided are methods of treating a wound by applying a topical gel according to an embodiment of the invention. Such methods may be used in combination with any other known methods of wound treatment, including the application of other therapeutic agents, such as those that have anti-inflammatory, pain-relieving, immunosuppressant, vasodilating, wound healing and/or anti-biofilm forming properties. For the methods used herein, additional therapeutic agents and methods may be used prior to, concurrently with or after application with a gel according to embodiments of the invention. Gels according to embodiments of the invention may also be used in any combination with any wound dressings known to those of skill in the art.
In some embodiments of the invention, the topical gels provided herein may be used in conjunction with at least one agent that can disrupt biofilm macrostructure prior to or in conjunction with the application of a wound dressing. In some embodiments, the anti-biofilm agent may disrupt the extracellular matrix of the biofilm. Examples of anti-biofilm agents that may act in this manner include lactoferrin, periodate, xylitol, DNase, protease, an enzyme that degrades extracellular polysaccharides. In some embodiments of the invention, the formulation of the anti-biofilm agent is acidic to promote enzyme activity of the DNase (e.g., mammalian DNases such as DNase II) and the acidic conditions simultaneously may also enhance the rate NO release from diazeniumdiolate macromolecules. In some embodiments, the protease may include at least one of proteinase K, trypsin, Pectinex Ultra SP (PUS) and pancreatin. In some embodiments, enzymes that degrade extracellular polysaccharides may include N-acetylglucosaminidases (e.g., dispersin B).
In some embodiments of the invention, the anti-biofilm agent may act by affecting the transcriptional, translational and/or post-translational regulation of quorum-sensing genes or gene products in the infecting organism(s). For example, the anti-biofilm agents may include at least one of hamamelitannin, cyclic di-GMP and sublethal concentrations of nitric oxide.
The anti-biofilm agents may also act by other mechanisms. For example, the anti-biofilm agent may cause the infecting organism to transition from a sessile state to a metabolically active state. As another example, the anti-biofilm agent may act by causing the infecting organism(s) to transition from a non-motile state to a motile phenotype.
In some embodiments of the invention, the topical gels provided herein may be used in conjunction with a wound debridement procedure. For example, in some embodiments, wounds may first be treated with a debridement procedure; and then a gel according to an embodiment of the invention may be applied to the debrided wound. The medicaments according to embodiments of the invention may increase the rate of wound healing, decrease inflammation and/or exert and antimicrobial effect. The wound dressings according to embodiments of the invention may be used in conjunction with any suitable debridement procedure. For example, the debridement procedure may be selective or nonselective.
In some embodiments, the debridement procedure may include at least one of surgical, enzymatic, autolytic, sharp, mechanical and biological processes. Any suitable surgical method may be used, but in some embodiments, the surgical method involves a surgeon cutting away nonviable tissue in the wound. Any suitable enzymatic method may be used, but in some embodiments, the enzymatic method may involve the use of one or more proteases, their required cofactors, and optionally any enhancing agents, to digest the nonviable tissue in the wound. Exemplary proteases include trypsin, papain or other vegetable-derived proteases and collagenase. Any suitable autolytic method may be used, but in some embodiments, the autolytic method involves maintaining a moist wound environment in order to promote the breakdown of nonviable tissue by enzymes that are naturally produced by the body. Any suitable mechanical method may be used, but in some embodiments, the mechanical methods include wet-to-dry gauze, irrigation, pulsatile lavage, whirlpool therapy and/or low frequency ultrasound. Any suitable sharp method may be used, but in some embodiments, the sharp method involves cutting away nonviable tissue by qualified clinical staff (e.g. RN or nurse practitioner). Any suitable biological method may be used, but in some embodiments, the biological method involves the use of maggots which selectively digest the nonviable tissue in the wound. These debridement methods may be used alone or in combination.
After the wound is debrided, a topical gel according to an embodiment of the invention may be applied. Additional processes may be performed and therapeutic agents may be applied. For example, after wound debridement, an anti-biofilm agent may be applied to the wound prior to or in conjunction with the application of the topical gels provided herein. Exemplary anti-biofilm agents include acetylsalicylic acid (aspirin), cyclic di-GMP, lactoferrin, gallium, selenium, as described above. Other compounds, such as hamamelitannin (witch hazel extract), arginine and c-di-GMP, may also be applied.
The gels may be applied to a subject in any suitable manner, such as, for example, rubbing, spreading or placing the gel on the wound or a wound dressing to be in contact with the wound. In some embodiments, the topical gel may be administered to a wound via spray delivery. A non-aqueous delivery propellant may be used for water the sensitive diazeniumdiolate-functionalized polysiloxane macromolecules. Further, in some embodiments, particular components of the gels may be separated at some point prior to application of the medicament. For example, the diazeniumdiolate polysiloxane macromolecule may be stored separately from an aqueous component or propellant until application (e.g., via spraying or applying a gel). In some embodiments, the diazeniumdiolate polysiloxane macromolecule may be combined with an aqueous constituent prior to application of the diazeniumdiolate polysiloxane macromolecules, and in some embodiments, an aqueous constituent may be applied to the wound bed sequentially.
Gels according to some embodiments of the invention may also be used to treat burns. A major goal in the treatment of burns is resuscitation and increase of fluid levels because of the significant loss of water from the body when the barrier function of the skin is compromised. Topical nitric oxide formulations that enhance the barrier function of the skin can not only restore this critical function for maintaining patient vitality but also prevent the infection of burn wound patients as compromised barrier function also creates an easy route for microbial contamination and colonization.
Hydrophobic gels in particular may be advantageous to use in the treatment of burns. Hydrophobic, non-aqueous gels can create an occlusive environment over the burn wounds and so prevent desiccation and create a moist wound environment. In some embodiments, for the treatment of burns, the diazeniumdiolate-functionalized polysiloxane macromolecules can be loaded in such a gel at different concentrations during different times during the healing process. For example, to prevent infection, a gel may be applied that has a NO loading in a range of 10 μmol NO/g gel to 1 mmol NO/g gel. During later phases of tissue remodeling, for example several weeks after injury, nitric oxide may be loaded at concentrations in a range of 1 nmol NO/g gel to 10 μmol NO/g gel to facilitate healing and matrix remodeling. The moist wound environment created by the occlusive hydrophobic gels enables the release of nitric oxide from the diazeniumdiolate-functionalized polysiloxane macromolecules which is otherwise unexpectedly stable at room temperature in a non-aqueous gel matrix. The diffusion of water throughout the gel matrix thus controls the rate of proton initiated diazeniumdiolate decomposition, favoring faster diazeniumdiolate polysiloxane macromolecular compositions, such as those that have aqueous half-lives in the range of 0.5 minutes to 10 minutes. A rapid NO-release profile for hydrophobic gel matrices may enable these levels of antimicrobial NO release. However, for sustained release of nitric oxide from the gel from hours to days, the hydrophobic matrix coupled with a slowly-degrading diazeniumdiolate-functionalized polysiloxane macromolecule may produce a unique NO-release signature that exhibits a flat release profile.
Gels according to embodiments of the invention may be used to treat acne. Lipophilic diazeniumdiolate-functionalized polysiloxane macromolecules may target the pilosebaceous gland and penetrate the sebum rich environment, for example, as a potential treatment for acne vulgaris. As described above, gels according to embodiments of the invention may include other therapeutic agents. In the case of the treatment of acne, the gels may include other anti-acne agents such as retenoids, such as those described herein. Furthermore, agents such as retenoids may be used in conjunction (prior, concurrently or after) with a gel according to an embodiment of the invention.
Gels according to embodiments of the invention may be used to treat other skin ailments, either via anti-microbial action, anti-inflammatory action, or by any other mechanism. For example, topical gels described herein may be used to treat other skin ailments such as impetigo, psoriasis, tinea pedis, onychomycosis and the like.
Subjects suitable to be treated with a gel according to an embodiment of the invention include, but are not limited to, avian and mammalian subjects. Mammals of the present invention include, but are not limited to, canines, felines, bovines, caprines, equines, ovines, porcines, rodents (e.g. rats and mice), lagomorphs, primates, humans, and the like, and mammals in utero. Any mammalian subject in need of being treated according to the present invention is suitable. Human subjects are preferred. Human subjects of both genders and at any stage of development (i.e., neonate, infant, juvenile, adolescent, adult) can be treated according to the present invention.
Illustrative avians according to the present invention include chickens, ducks, turkeys, geese, quail, pheasant, ratites (e.g., ostrich) and domesticated birds (e.g., parrots and canaries), and birds in ovo.
The invention can also be carried out on animal subjects, particularly mammalian subjects such as mice, rats, dogs, cats, livestock and horses for veterinary purposes, and for drug screening and drug development purposes.
The antimicrobial efficacy of Nitricil™-70 Dry Powder was assessed against representative multi-drug resistant Gram-positive (HA-MRSA, ATCC 33591, SCCmec Type III) and Gram-negative (P. aeruginosa, ATCC 15442) organisms using the ASTM E 2315 Test Method. Various concentrations of NJ070 particles were incubated, in duplicate, with P. aeruginosa (See
Solid Nitricil™ 70 kills both P. aeruginosa and MRSA in a dose- and time-dependent manner, with 99.9 percent killing of P. aeruginosa achieved at earlier time points and lower concentrations than are required for HA-MRSA. These data suggest that Nitricil™ is active against both Gram-positive and Gram-negative bacteria, but may be effective against Gram-negative bacteria at lower doses.
A hydrophobic, non-aqueous NO-releasing gel was formulated using 75 percent Dimethicone/Vinyl Dimethicone Crosspolymer and −25 percent cyclomethicone co-solvent as a viscosity modifier. Nitricil™-70 at a weight of 24 mg (0.1% w/w final gel loading) or 240 mg (1.0% w/w final gel loading) was dispersed in 6 ml of the cyclomethicone and sonicated to provide a homogenous particle suspension based on the likeness of the silicone solvent and exterior of the co-condensed siloxane particles. The concentrations of the components are listed below in TABLE 1. The Nitricil™ suspension was then combined with dimethicone gel in a 1:3 ratio to provide the finished compositions for animal testing. Blank vehicle contained only dimethicone and cyclomethicone co-solvent absent of any NO-releasing macromolecules.
Two 2×2 cm full thickness excisional wounds were made on the back of male nude rats across a total of 36 animals broken down into the groups shown in TABLE 2.
Immediately following wounding, wounds were challenged with 100 μL of a 107 innoculum of P. aeruginosa and covered with Bioclusive Transparent Dressings (Johnson and Johnson) for 24 h to grow mature P. aeruginosa biofilms. Treatment with 200 mg of Blank Gel, 0.1 weight percent, and 1.0 weight percent Nitricil™ loaded silicone gels commenced on Day 1 and was repeated once daily for the duration of the study. The occlusive thin film dressings were also replaced following each treatment. On Day 3, two animals from each group were euthanized and 8 mm punch biopsies were taken from the center of each wound, homogenized in sterile saline, and plated to determine the number of colonies per gram of tissue. Referring to
Wound photographs were taken at each topical gel application and prior to necropsy. Quantitative measurements of the wound area for each treatment group were performed using the scale bar provided in each photograph. The wound area (cm2) were measured for all wounds available and converted to percent Wound closure when compared to the initial wound area measured for each individual wound. The data for Day 3 and Day 9 are shown in
On Day 3, the 0.1 percent Nitricil™ loaded silicone gel showed a dramatic enhancement, nearly 25 percent greater wound closure in comparison to all of the other treatment groups. A series of images for all of the treatment groups from Day 0 (wounding) until the completion of the study at Day 9 are shown in
A: Silicone-Based Non-Aqueous Emulsion
The formulation concentrations, shown in % (w/w), are provided in TABLE 3.
B: Silicone-Based Ointment
The formulation concentrations, shown in % (w/w), are provided in TABLE 4.
C: ST-Elastomer Based Non-Aqueous Gel
The formulation concentrations, shown in % (w/w), are provided in TABLE 5.
D: Wacker Belsil-Based Non-Aqueous Gel
The formulation concentrations, shown in % (w/w), are provided in TABLE 6.
A hydrophilic, NO-releasing gel was formulated using glycerol as the base. Carbopol 940 was used as rheology modifier. Briefly, Carbopol 940 was dissolved in glycerol at a concentration of 0.5% (w/v) by overnight stirring of 0.1 g Carbopol 940 in 20 ml glycerol at 50° C. In a separate container, 200 μl of triethanolamine was added to 10 ml glycerol, to adjust the pH to 11.0.
Nitricil™-70 at a weight of 18.93 mg (1% w/w final gel loading) or 189.3 mg (10% w/w final gel loading) was dispersed in 1 ml of the glycerol at pH 11.0, using a paddle stirrer at 500 RPM. A half milliliter of the 0.5% Carbopol 940 solution was added to the Nitricil™-70 dispersion under continuous agitation at 500 RPM. The resulting viscous gel was transferred to a 3 ml polypropylene syringe. The pH of the gel was measured to be 7.0.
The formulation concentrations, shown in % (w/w), are provided in TABLE 7
The NO-release of the gel was measured by weighing a small amount of the gel (2.8 mg) into the Chemiluminescent Nitric Oxide Analyzer, as shown in
MRSA colony biofilms were grown on UV-sterilized 25 mm polycarbonate filters (0.22 μm) as described previously (Anderl et al 2000, Rani et al 2007). Briefly, an overnight culture of S. aureus ATCC 33591 was diluted to OD600 of approximately 0.1. Ten microliters of the diluted culture was spotted in the center of a polycarbonate filter resting on a tryptic soy agar plate. Biofilms were grown for two days at 37° C., with a transfer to a new TSA plate after 24 h. At the initiation of the experiment, each filter was transferred to an individual well in a 6-well plate. Gel formulations (0.1 ml) were added drop-wise over top of each biofilm (three biofilms per treatment) without disrupting the biofilm structure. Plates were incubated inside at humidified box (37° C., 24 h). After 24 h, Letheen broth (1 ml) was used to wash each well and then added, along with each filter, to 9 ml of Letheen broth in a 50 ml conical. Conicals were sonicated (1 min) and vortexed (1 min). The resulting bacterial suspension was serially diluted and plated to obtain colony counts. The results are shown in TABLES 8 and 9.
A: Ethocel Based Non-Aqueous Gel
Formulations with various Ethocel polymers are shown in TABLES 10-12.
A series of topical gels were formulated to contain nitric oxide-releasing silica particles in weight percentages ranging from 0.1% to 2.0% wt/wt and the percentage of nitric oxide recovered from the formulated gel prototypes was measured via nitric oxide chemiluminescence. Not all excipient combinations were able to maintain diazeniumdiolate NO-donor stability (TABLE 16). Unexpectedly, a series of topical gels containing diazeniumdiolate modified silica that exhibited stability at room temperature were discovered.
10%
29%
29%
52%
13%
This application is a continuation of U.S. application Ser. No. 13/256,928, filed Sep. 15, 2011, which is a 35 U.S.C. §371 national stage application of International Application No. PCT/US2010/046173, filed on Aug. 20, 2010, which claims priority from U.S. Provisional Application Ser. No. 61/235,933, filed Aug. 21, 2009, the disclosures of each of which are incorporated by reference herein in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4396615 | Petrow et al. | Aug 1983 | A |
| 4507466 | Tomalia et al. | Mar 1985 | A |
| 4558120 | Tomalia et al. | Dec 1985 | A |
| 4568737 | Tomalia et al. | Feb 1986 | A |
| 4587329 | Tomalia et al. | May 1986 | A |
| 4600001 | Gilman | Jul 1986 | A |
| 4631337 | Tomalia et al. | Dec 1986 | A |
| 4694064 | Tomalia et al. | Sep 1987 | A |
| 4713975 | Tomalia et al. | Dec 1987 | A |
| 4737550 | Tomalia | Apr 1988 | A |
| 4857599 | Tomalia et al. | Aug 1989 | A |
| 4871779 | Killat et al. | Oct 1989 | A |
| 4985023 | Blank et al. | Jan 1991 | A |
| 4990338 | Blank et al. | Feb 1991 | A |
| 5035892 | Blank et al. | Jul 1991 | A |
| 5045322 | Blank et al. | Sep 1991 | A |
| 5061487 | Blank et al. | Oct 1991 | A |
| 5079004 | Blank et al. | Jan 1992 | A |
| 5380758 | Stamler et al. | Jan 1995 | A |
| 5405919 | Keefer et al. | Apr 1995 | A |
| 5418301 | Hult et al. | May 1995 | A |
| 5428070 | Cooke et al. | Jun 1995 | A |
| 5504117 | Gorfine | Apr 1996 | A |
| 5519020 | Smith et al. | May 1996 | A |
| 5525357 | Keefer et al. | Jun 1996 | A |
| 5574068 | Stamler et al. | Nov 1996 | A |
| 5593876 | Stamler et al. | Jan 1997 | A |
| 5599984 | Bianchi et al. | Feb 1997 | A |
| 5629322 | Guthikonda et al. | May 1997 | A |
| 5632981 | Saavedra et al. | May 1997 | A |
| 5650442 | Mitchell et al. | Jul 1997 | A |
| 5650447 | Keefer et al. | Jul 1997 | A |
| 5665077 | Rosen et al. | Sep 1997 | A |
| 5676963 | Keefer et al. | Oct 1997 | A |
| 5691423 | Smith et al. | Nov 1997 | A |
| 5693676 | Gorfine | Dec 1997 | A |
| 5700830 | Korthuis et al. | Dec 1997 | A |
| 5718892 | Keefer et al. | Feb 1998 | A |
| 5726156 | Girten et al. | Mar 1998 | A |
| 5750573 | Bianchi et al. | May 1998 | A |
| 5753684 | Bianchi et al. | May 1998 | A |
| 5760001 | Girten et al. | Jun 1998 | A |
| 5770645 | Stamler et al. | Jun 1998 | A |
| 5786332 | Girten et al. | Jul 1998 | A |
| 5789447 | Wink, Jr. et al. | Aug 1998 | A |
| 5797887 | Rosen et al. | Aug 1998 | A |
| 5810010 | Anbar | Sep 1998 | A |
| 5814666 | Green et al. | Sep 1998 | A |
| 5814667 | Mitchell et al. | Sep 1998 | A |
| 5821261 | Durette et al. | Oct 1998 | A |
| 5837736 | Mitchell et al. | Nov 1998 | A |
| 5840759 | Mitchell et al. | Nov 1998 | A |
| 5849794 | Bianchi et al. | Dec 1998 | A |
| 5852058 | Cooke et al. | Dec 1998 | A |
| 5854289 | Bianchi et al. | Dec 1998 | A |
| 5859062 | Bianchi et al. | Jan 1999 | A |
| 5861168 | Cooke et al. | Jan 1999 | A |
| 5863890 | Stamler et al. | Jan 1999 | A |
| 5891459 | Cooke et al. | Apr 1999 | A |
| 5891472 | Russell | Apr 1999 | A |
| 5910316 | Keefer et al. | Jun 1999 | A |
| 5932538 | Garvey et al. | Aug 1999 | A |
| 5958427 | Salzman et al. | Sep 1999 | A |
| 5961466 | Anbar | Oct 1999 | A |
| 5962520 | Smith et al. | Oct 1999 | A |
| 5968528 | Deckner et al. | Oct 1999 | A |
| 5994294 | Garvey et al. | Nov 1999 | A |
| 5994444 | Trescony et al. | Nov 1999 | A |
| 5999843 | Anbar | Dec 1999 | A |
| 6008255 | Bianchi et al. | Dec 1999 | A |
| 6022900 | Bianchi et al. | Feb 2000 | A |
| 6035225 | Anbar | Mar 2000 | A |
| 6043358 | Caldwell et al. | Mar 2000 | A |
| 6045827 | Russell | Apr 2000 | A |
| 6070928 | Campbell | Jun 2000 | A |
| 6087479 | Stamler et al. | Jul 2000 | A |
| 6103266 | Tapolsky et al. | Aug 2000 | A |
| 6103275 | Seitz et al. | Aug 2000 | A |
| 6110453 | Keefer et al. | Aug 2000 | A |
| 6143037 | Goldstein et al. | Nov 2000 | A |
| 6147068 | Smith et al. | Nov 2000 | A |
| 6151522 | Alfano et al. | Nov 2000 | A |
| 6160021 | Lerner et al. | Dec 2000 | A |
| 6171232 | Papandreou et al. | Jan 2001 | B1 |
| 6174539 | Stamler et al. | Jan 2001 | B1 |
| 6180082 | Woltering et al. | Jan 2001 | B1 |
| 6180676 | Bianchi et al. | Jan 2001 | B1 |
| 6190704 | Murrell | Feb 2001 | B1 |
| 6200558 | Saavedra et al. | Mar 2001 | B1 |
| 6207664 | Hayward et al. | Mar 2001 | B1 |
| 6207855 | Toone et al. | Mar 2001 | B1 |
| 6218016 | Tedeschi et al. | Apr 2001 | B1 |
| 6232336 | Hrabie et al. | May 2001 | B1 |
| 6232434 | Stamler et al. | May 2001 | B1 |
| 6238683 | Burnett et al. | May 2001 | B1 |
| 6248787 | Bianchi et al. | Jun 2001 | B1 |
| 6255277 | Stamler et al. | Jul 2001 | B1 |
| 6261594 | Smith et al. | Jul 2001 | B1 |
| 6270779 | Fitzhugh et al. | Aug 2001 | B1 |
| 6287601 | Russell | Sep 2001 | B1 |
| 6290981 | Keefer et al. | Sep 2001 | B1 |
| 6291424 | Stamler et al. | Sep 2001 | B1 |
| 6294517 | Garvey et al. | Sep 2001 | B1 |
| 6299980 | Shah et al. | Oct 2001 | B1 |
| 6323211 | Garvey et al. | Nov 2001 | B1 |
| 6350467 | Demopoulos et al. | Feb 2002 | B1 |
| 6352709 | Stamler et al. | Mar 2002 | B1 |
| 6358536 | Thomas | Mar 2002 | B1 |
| 6359167 | Toone et al. | Mar 2002 | B2 |
| 6359182 | Stamler et al. | Mar 2002 | B1 |
| 6369071 | Haj-Yehia | Apr 2002 | B1 |
| 6372733 | Caldwell et al. | Apr 2002 | B1 |
| 6377321 | Khan et al. | Apr 2002 | B1 |
| 6379660 | Saavedra et al. | Apr 2002 | B1 |
| 6379691 | Tedeschi et al. | Apr 2002 | B1 |
| 6391895 | Towart et al. | May 2002 | B1 |
| 6403759 | Stamler et al. | Jun 2002 | B2 |
| 6410622 | Endres | Jun 2002 | B1 |
| 6417162 | Garvey et al. | Jul 2002 | B1 |
| 6432077 | Stenzler | Aug 2002 | B1 |
| 6433182 | Garvey et al. | Aug 2002 | B1 |
| 6436975 | Del Soldato | Aug 2002 | B1 |
| 6441254 | Dobert | Aug 2002 | B1 |
| 6448267 | Anggard et al. | Sep 2002 | B1 |
| 6451337 | Smith et al. | Sep 2002 | B1 |
| 6455542 | Anggard et al. | Sep 2002 | B1 |
| 6469065 | Garvey et al. | Oct 2002 | B1 |
| 6471978 | Stamler et al. | Oct 2002 | B1 |
| 6472390 | Stamler et al. | Oct 2002 | B1 |
| 6474508 | Marsh | Nov 2002 | B1 |
| 6488951 | Toone et al. | Dec 2002 | B2 |
| 6492405 | Haj-Yehia | Dec 2002 | B2 |
| 6511991 | Hrabie et al. | Jan 2003 | B2 |
| 6514934 | Garvey et al. | Feb 2003 | B1 |
| 6538033 | Bing | Mar 2003 | B2 |
| 6560478 | Alfano et al. | May 2003 | B1 |
| 6562344 | Stamler et al. | May 2003 | B1 |
| 6562785 | Shapiro | May 2003 | B1 |
| 6583113 | Stamler et al. | Jun 2003 | B2 |
| 6583311 | Toone et al. | Jun 2003 | B2 |
| 6605447 | Weiss et al. | Aug 2003 | B2 |
| 6610660 | Saavedra et al. | Aug 2003 | B1 |
| 6627602 | Stamler et al. | Sep 2003 | B2 |
| 6642208 | Cooke et al. | Nov 2003 | B2 |
| 6642260 | Haj-Yehia | Nov 2003 | B2 |
| 6645518 | Tedeschi et al. | Nov 2003 | B2 |
| 6646006 | Cooke et al. | Nov 2003 | B2 |
| 6656217 | Herzog, Jr. et al. | Dec 2003 | B1 |
| 6673338 | Arnold et al. | Jan 2004 | B1 |
| 6673891 | Stamler et al. | Jan 2004 | B2 |
| 6699846 | Elliott et al. | Mar 2004 | B2 |
| 6703046 | Fitzhugh et al. | Mar 2004 | B2 |
| 6706274 | Herrmann et al. | Mar 2004 | B2 |
| 6709681 | Benjamin et al. | Mar 2004 | B2 |
| 6723703 | Gaston et al. | Apr 2004 | B2 |
| 6737447 | Smith et al. | May 2004 | B1 |
| 6747062 | Murrell | Jun 2004 | B2 |
| 6750254 | Hrabie et al. | Jun 2004 | B2 |
| 6758214 | Fine et al. | Jul 2004 | B2 |
| 6759430 | Anggard et al. | Jul 2004 | B2 |
| 6780849 | Herrmann et al. | Aug 2004 | B2 |
| 6793644 | Stenzler | Sep 2004 | B2 |
| 6796966 | Thomas | Sep 2004 | B2 |
| 6841166 | Zhang et al. | Jan 2005 | B1 |
| 6849662 | Enikolopov et al. | Feb 2005 | B2 |
| 6855366 | Smith et al. | Feb 2005 | B2 |
| 6875840 | Stack et al. | Apr 2005 | B2 |
| 6887485 | Fitzhugh et al. | May 2005 | B2 |
| 6887994 | Stamler et al. | May 2005 | B2 |
| 6894073 | Lee et al. | May 2005 | B2 |
| 6896899 | Demopolos et al. | May 2005 | B2 |
| 6897218 | Casella et al. | May 2005 | B2 |
| 6911433 | Saavedra et al. | Jun 2005 | B2 |
| 6911478 | Hrabie et al. | Jun 2005 | B2 |
| 6946484 | Adams et al. | Sep 2005 | B2 |
| 6949530 | Hrabie et al. | Sep 2005 | B2 |
| 6951902 | McDonald et al. | Oct 2005 | B2 |
| 6964984 | Stamler et al. | Nov 2005 | B2 |
| 6974801 | Honda et al. | Dec 2005 | B2 |
| 7012098 | Manning et al. | Mar 2006 | B2 |
| 7015347 | Toone et al. | Mar 2006 | B2 |
| 7025869 | Fine et al. | Apr 2006 | B2 |
| 7030238 | Stamler et al. | Apr 2006 | B2 |
| 7033999 | Stamler et al. | Apr 2006 | B2 |
| 7040313 | Fine et al. | May 2006 | B2 |
| 7048951 | Seitz et al. | May 2006 | B1 |
| 7049308 | Stamler et al. | May 2006 | B2 |
| 7052711 | West et al. | May 2006 | B2 |
| 7070798 | Michal et al. | Jul 2006 | B1 |
| 7081524 | Saavedra et al. | Jul 2006 | B2 |
| 7087588 | Del Soldato | Aug 2006 | B2 |
| 7087709 | Stamler et al. | Aug 2006 | B2 |
| 7122018 | Stenzler et al. | Oct 2006 | B2 |
| 7122027 | Trescony et al. | Oct 2006 | B2 |
| 7122529 | Ruane et al. | Oct 2006 | B2 |
| 7128904 | Batchelor et al. | Oct 2006 | B2 |
| 7135189 | Knapp | Nov 2006 | B2 |
| 7135498 | Chopp et al. | Nov 2006 | B1 |
| 7157500 | Stamler et al. | Jan 2007 | B2 |
| 7169809 | Berthelette et al. | Jan 2007 | B2 |
| 7176237 | Honda et al. | Feb 2007 | B2 |
| 7179475 | Burnett et al. | Feb 2007 | B1 |
| 7189761 | Gorfine | Mar 2007 | B2 |
| 7199154 | Berthelette et al. | Apr 2007 | B2 |
| 7204980 | Clark | Apr 2007 | B2 |
| 7226586 | Fitzhugh et al. | Jun 2007 | B2 |
| 7234079 | Cheng | Jun 2007 | B2 |
| 7250442 | Brown et al. | Jul 2007 | B2 |
| 7259250 | Stamler et al. | Aug 2007 | B2 |
| 7279176 | West et al. | Oct 2007 | B1 |
| 7282519 | Garvey et al. | Oct 2007 | B2 |
| 7314857 | Madhyastha | Jan 2008 | B2 |
| 7335383 | Meyerhoff et al. | Feb 2008 | B2 |
| 7345053 | Garvey | Mar 2008 | B2 |
| 7348319 | Hrabie et al. | Mar 2008 | B2 |
| 7364585 | Weber | Apr 2008 | B2 |
| 7396829 | Garvey et al. | Jul 2008 | B2 |
| 7417109 | Stamler et al. | Aug 2008 | B2 |
| 7425218 | Keefer et al. | Sep 2008 | B2 |
| 7432301 | Gaston et al. | Oct 2008 | B2 |
| 7452916 | Cooke | Nov 2008 | B2 |
| 7468435 | Waterhouse et al. | Dec 2008 | B2 |
| 7485324 | Miller et al. | Feb 2009 | B2 |
| 7520866 | Stenzler et al. | Apr 2009 | B2 |
| 7531164 | Daaka et al. | May 2009 | B2 |
| 7569559 | Arnold et al. | Aug 2009 | B2 |
| 7582623 | Mascharak | Sep 2009 | B2 |
| 7595313 | Garvey et al. | Sep 2009 | B2 |
| 7622501 | Dufresne et al. | Nov 2009 | B2 |
| 7622502 | Berthelette et al. | Nov 2009 | B2 |
| 7645748 | Orchansky et al. | Jan 2010 | B2 |
| 7645749 | Orchansky et al. | Jan 2010 | B2 |
| 7651697 | West et al. | Jan 2010 | B2 |
| 7655423 | Chopp et al. | Feb 2010 | B2 |
| 7674482 | Shell et al. | Mar 2010 | B2 |
| 7678391 | Graham et al. | Mar 2010 | B2 |
| 7678830 | Honda et al. | Mar 2010 | B2 |
| 7696247 | Herrmann et al. | Apr 2010 | B2 |
| 7704518 | Tamarkin et al. | Apr 2010 | B2 |
| 7745656 | Toone et al. | Jun 2010 | B2 |
| 7763283 | Batchelor et al. | Jul 2010 | B2 |
| 7785616 | Stamler et al. | Aug 2010 | B2 |
| 7795286 | Lucet-Levannier | Sep 2010 | B2 |
| 7799335 | Herrmann et al. | Sep 2010 | B2 |
| 7807716 | Farber | Oct 2010 | B2 |
| 7811600 | Cheng et al. | Oct 2010 | B2 |
| 7820284 | Terry | Oct 2010 | B2 |
| 7829553 | Arnold et al. | Nov 2010 | B2 |
| 7838023 | Garvey et al. | Nov 2010 | B2 |
| 7846400 | Hyde et al. | Dec 2010 | B2 |
| 7862598 | Hyde et al. | Jan 2011 | B2 |
| 7892198 | Stenzler | Feb 2011 | B2 |
| 7897399 | Hyde et al. | Mar 2011 | B2 |
| 7928079 | Hrabie et al. | Apr 2011 | B2 |
| 7928096 | Waterhouse et al. | Apr 2011 | B2 |
| 7947299 | Knapp | May 2011 | B2 |
| 7972137 | Rosen | Jul 2011 | B2 |
| 7975699 | Hyde et al. | Jul 2011 | B2 |
| 8003811 | Almirante | Aug 2011 | B2 |
| 8017074 | Arnold et al. | Sep 2011 | B2 |
| 8021679 | Chen et al. | Sep 2011 | B2 |
| 8034384 | Meyerhoff et al. | Oct 2011 | B2 |
| 8043246 | Av-Gay et al. | Oct 2011 | B2 |
| 8241650 | Peters | Aug 2012 | B2 |
| 8343945 | Tamarkin et al. | Jan 2013 | B2 |
| 8362091 | Tamarkin et al. | Jan 2013 | B2 |
| 8388677 | Herrmann | Mar 2013 | B2 |
| 8486374 | Tamarkin et al. | Jul 2013 | B2 |
| 8591876 | Bauman et al. | Nov 2013 | B2 |
| 8617100 | Eini et al. | Dec 2013 | B2 |
| 8636982 | Tamarkin et al. | Jan 2014 | B2 |
| 8795635 | Tamarkin et al. | Aug 2014 | B2 |
| 8795693 | Tamarkin et al. | Aug 2014 | B2 |
| 8900553 | Tamarkin et al. | Dec 2014 | B2 |
| 9101662 | Tamarkin et al. | Aug 2015 | B2 |
| 9161916 | Tamarkin et al. | Oct 2015 | B2 |
| 9265725 | Tamarkin et al. | Feb 2016 | B2 |
| 9320705 | Tamarkin et al. | Apr 2016 | B2 |
| 20010012851 | Lundy et al. | Aug 2001 | A1 |
| 20010025057 | Gorfine | Sep 2001 | A1 |
| 20010038832 | Bonavida et al. | Nov 2001 | A1 |
| 20010053772 | Bonavida et al. | Dec 2001 | A1 |
| 20020013304 | Wilson et al. | Jan 2002 | A1 |
| 20020018757 | Harichian et al. | Feb 2002 | A1 |
| 20020028223 | Vatter et al. | Mar 2002 | A1 |
| 20020028851 | Bianchi et al. | Mar 2002 | A1 |
| 20020049157 | Wu et al. | Apr 2002 | A1 |
| 20020061879 | Garvey et al. | May 2002 | A1 |
| 20020068365 | Kuhrts | Jun 2002 | A1 |
| 20020090401 | Tucker et al. | Jul 2002 | A1 |
| 20020115586 | Enikolopov | Aug 2002 | A1 |
| 20020122929 | Simpson et al. | Sep 2002 | A1 |
| 20020132234 | Moskowitz | Sep 2002 | A1 |
| 20020133040 | Woo et al. | Sep 2002 | A1 |
| 20020136763 | Demopoulos et al. | Sep 2002 | A1 |
| 20020138051 | Hole et al. | Sep 2002 | A1 |
| 20020143007 | Garvey et al. | Oct 2002 | A1 |
| 20020143062 | Lopez-Berestein et al. | Oct 2002 | A1 |
| 20020155174 | Benjamin et al. | Oct 2002 | A1 |
| 20020161042 | Gorfine | Oct 2002 | A1 |
| 20020165195 | Wang et al. | Nov 2002 | A1 |
| 20020182162 | Shahinpoor et al. | Dec 2002 | A1 |
| 20030027844 | Soldato | Feb 2003 | A1 |
| 20030039697 | Zhao et al. | Feb 2003 | A1 |
| 20030050305 | Tejada | Mar 2003 | A1 |
| 20030072783 | Stamler et al. | Apr 2003 | A1 |
| 20030093143 | Zhao et al. | May 2003 | A1 |
| 20030134779 | Diarra et al. | Jul 2003 | A1 |
| 20030170674 | Moskowitz | Sep 2003 | A1 |
| 20030203915 | Fang et al. | Oct 2003 | A1 |
| 20030219854 | Guarna et al. | Nov 2003 | A1 |
| 20040009238 | Miller et al. | Jan 2004 | A1 |
| 20040013747 | Tucker et al. | Jan 2004 | A1 |
| 20040033480 | Wong | Feb 2004 | A1 |
| 20040037836 | Stamler et al. | Feb 2004 | A1 |
| 20040037897 | Benjamin et al. | Feb 2004 | A1 |
| 20040043068 | Tedeschi et al. | Mar 2004 | A1 |
| 20040076582 | Dimatteo et al. | Apr 2004 | A1 |
| 20040082659 | Cooke et al. | Apr 2004 | A1 |
| 20040105898 | Benjamin et al. | Jun 2004 | A1 |
| 20040110691 | Stamler | Jun 2004 | A1 |
| 20040131703 | Bach et al. | Jul 2004 | A1 |
| 20040143010 | Esteve-Soler et al. | Jul 2004 | A1 |
| 20040147598 | Haj-Yehia | Jul 2004 | A1 |
| 20040157936 | Burnett et al. | Aug 2004 | A1 |
| 20040198705 | Willnow et al. | Oct 2004 | A1 |
| 20040228889 | Cals-Grierson | Nov 2004 | A1 |
| 20040254419 | Wang et al. | Dec 2004 | A1 |
| 20040265244 | Rosen | Dec 2004 | A1 |
| 20050036949 | Tucker et al. | Feb 2005 | A1 |
| 20050037093 | Benjamin | Feb 2005 | A1 |
| 20050038473 | Tamarkin et al. | Feb 2005 | A1 |
| 20050054714 | Munoz et al. | Mar 2005 | A1 |
| 20050065161 | Garvey et al. | Mar 2005 | A1 |
| 20050069595 | Chen et al. | Mar 2005 | A1 |
| 20050074506 | Natan et al. | Apr 2005 | A1 |
| 20050079132 | Wang et al. | Apr 2005 | A1 |
| 20050080021 | Tucker et al. | Apr 2005 | A1 |
| 20050080024 | Tucker et al. | Apr 2005 | A1 |
| 20050131064 | Gaston et al. | Jun 2005 | A1 |
| 20050142217 | Adams et al. | Jun 2005 | A1 |
| 20050142218 | Tucker et al. | Jun 2005 | A1 |
| 20050152891 | Toone et al. | Jul 2005 | A1 |
| 20050165452 | Sigg et al. | Jul 2005 | A1 |
| 20050171006 | Bunting et al. | Aug 2005 | A1 |
| 20050171199 | Murrell | Aug 2005 | A1 |
| 20050187222 | Garvey et al. | Aug 2005 | A1 |
| 20050220838 | Zhao et al. | Oct 2005 | A1 |
| 20050232869 | Tamarkin et al. | Oct 2005 | A1 |
| 20050245492 | Lephart et al. | Nov 2005 | A1 |
| 20050249818 | Sawan et al. | Nov 2005 | A1 |
| 20050265958 | West et al. | Dec 2005 | A1 |
| 20050271596 | Friedman et al. | Dec 2005 | A1 |
| 20050281867 | Kahn et al. | Dec 2005 | A1 |
| 20060008529 | Meyerhoff et al. | Jan 2006 | A1 |
| 20060009431 | Earl et al. | Jan 2006 | A1 |
| 20060035854 | Goldstein et al. | Feb 2006 | A1 |
| 20060039950 | Zhou et al. | Feb 2006 | A1 |
| 20060058363 | Wang et al. | Mar 2006 | A1 |
| 20060067909 | West et al. | Mar 2006 | A1 |
| 20060095120 | Herrmann | May 2006 | A1 |
| 20060100159 | Stamler et al. | May 2006 | A1 |
| 20060142183 | Diarra et al. | Jun 2006 | A1 |
| 20060147553 | Miller et al. | Jul 2006 | A1 |
| 20060147904 | Wong | Jul 2006 | A1 |
| 20060153904 | Smith et al. | Jul 2006 | A1 |
| 20060155260 | Blott et al. | Jul 2006 | A1 |
| 20060159726 | Shell | Jul 2006 | A1 |
| 20060160897 | Pelicci et al. | Jul 2006 | A1 |
| 20060172018 | Fine et al. | Aug 2006 | A1 |
| 20060198831 | Stamler et al. | Sep 2006 | A1 |
| 20060211601 | Stamler et al. | Sep 2006 | A1 |
| 20060235222 | Bell et al. | Oct 2006 | A1 |
| 20060269620 | Morris et al. | Nov 2006 | A1 |
| 20060275218 | Tamarkin et al. | Dec 2006 | A1 |
| 20060286158 | Calvert Murrell et al. | Dec 2006 | A1 |
| 20060286159 | Calvert Murrell et al. | Dec 2006 | A1 |
| 20070003538 | Madhyastha | Jan 2007 | A1 |
| 20070014686 | Arnold et al. | Jan 2007 | A1 |
| 20070014733 | O'Donnell et al. | Jan 2007 | A1 |
| 20070014828 | Fitzhugh et al. | Jan 2007 | A1 |
| 20070037821 | Garvey et al. | Feb 2007 | A1 |
| 20070048344 | Yahiaoui et al. | Mar 2007 | A1 |
| 20070053952 | Chen et al. | Mar 2007 | A1 |
| 20070053955 | Larson et al. | Mar 2007 | A1 |
| 20070053966 | Ang et al. | Mar 2007 | A1 |
| 20070059351 | Murrell et al. | Mar 2007 | A1 |
| 20070086954 | Miller | Apr 2007 | A1 |
| 20070087025 | Fitzhugh et al. | Apr 2007 | A1 |
| 20070088345 | Larson et al. | Apr 2007 | A1 |
| 20070089739 | Fine et al. | Apr 2007 | A1 |
| 20070116785 | Miller | May 2007 | A1 |
| 20070129690 | Rosenblatt et al. | Jun 2007 | A1 |
| 20070148136 | Whitlock | Jun 2007 | A1 |
| 20070154570 | Miller et al. | Jul 2007 | A1 |
| 20070166227 | Liu et al. | Jul 2007 | A1 |
| 20070166255 | Gupta | Jul 2007 | A1 |
| 20070172469 | Clark | Jul 2007 | A1 |
| 20070191377 | Worcel | Aug 2007 | A1 |
| 20070196327 | Kalivretenos et al. | Aug 2007 | A1 |
| 20070197543 | Esteve-Soler et al. | Aug 2007 | A1 |
| 20070202155 | Ang et al. | Aug 2007 | A1 |
| 20070203242 | Calton | Aug 2007 | A1 |
| 20070207179 | Andersen et al. | Sep 2007 | A1 |
| 20070219208 | Kalyanaraman et al. | Sep 2007 | A1 |
| 20070225250 | Brown | Sep 2007 | A1 |
| 20070239107 | Lundberg et al. | Oct 2007 | A1 |
| 20070243262 | Hurley et al. | Oct 2007 | A1 |
| 20070248676 | Stamler et al. | Oct 2007 | A1 |
| 20070264225 | Cheng et al. | Nov 2007 | A1 |
| 20070270348 | Kahn et al. | Nov 2007 | A1 |
| 20070275100 | Miller | Nov 2007 | A1 |
| 20070292359 | Friedman et al. | Dec 2007 | A1 |
| 20070292461 | Tamarkin et al. | Dec 2007 | A1 |
| 20080025972 | Daaka et al. | Jan 2008 | A1 |
| 20080031907 | Tamarkin et al. | Feb 2008 | A1 |
| 20080033334 | Gurtner et al. | Feb 2008 | A1 |
| 20080039521 | Yasuda et al. | Feb 2008 | A1 |
| 20080044444 | Tamarkin et al. | Feb 2008 | A1 |
| 20080045909 | Fossel | Feb 2008 | A1 |
| 20080063607 | Tamarkin et al. | Mar 2008 | A1 |
| 20080069779 | Tamarkin et al. | Mar 2008 | A1 |
| 20080069848 | Peters | Mar 2008 | A1 |
| 20080069863 | Peters | Mar 2008 | A1 |
| 20080069905 | Peters | Mar 2008 | A1 |
| 20080071206 | Peters | Mar 2008 | A1 |
| 20080076721 | Abraham et al. | Mar 2008 | A1 |
| 20080089956 | Da et al. | Apr 2008 | A1 |
| 20080138296 | Tamarkin et al. | Jun 2008 | A1 |
| 20080139450 | Madhyastha et al. | Jun 2008 | A1 |
| 20080145449 | Stamler | Jun 2008 | A1 |
| 20080152596 | Friedman et al. | Jun 2008 | A1 |
| 20080166303 | Tamarkin et al. | Jul 2008 | A1 |
| 20080171021 | Bach et al. | Jul 2008 | A1 |
| 20080171351 | Smith | Jul 2008 | A1 |
| 20080175881 | Ippoliti et al. | Jul 2008 | A1 |
| 20080182797 | Nudler et al. | Jul 2008 | A1 |
| 20080193385 | Maibach | Aug 2008 | A1 |
| 20080193566 | Miller et al. | Aug 2008 | A1 |
| 20080206155 | Tamarkin et al. | Aug 2008 | A1 |
| 20080206159 | Tamarkin et al. | Aug 2008 | A1 |
| 20080206161 | Tamarkin et al. | Aug 2008 | A1 |
| 20080207491 | Diarra et al. | Aug 2008 | A1 |
| 20080207713 | Wang et al. | Aug 2008 | A1 |
| 20080214646 | Knaus et al. | Sep 2008 | A1 |
| 20080226751 | Tucker et al. | Sep 2008 | A1 |
| 20080241208 | Shanley et al. | Oct 2008 | A1 |
| 20080253973 | Tamarkin et al. | Oct 2008 | A1 |
| 20080260655 | Tamarkin et al. | Oct 2008 | A1 |
| 20080275093 | Garvey et al. | Nov 2008 | A1 |
| 20080280984 | Fossel | Nov 2008 | A1 |
| 20080286321 | Reneker et al. | Nov 2008 | A1 |
| 20080287861 | Stenzler et al. | Nov 2008 | A1 |
| 20080292560 | Tamarkin et al. | Nov 2008 | A1 |
| 20080299220 | Tamarkin et al. | Dec 2008 | A1 |
| 20080306012 | Hrabie et al. | Dec 2008 | A1 |
| 20080311163 | Peters | Dec 2008 | A1 |
| 20080317626 | Arnold et al. | Dec 2008 | A1 |
| 20080317679 | Tamarkin et al. | Dec 2008 | A1 |
| 20090004298 | Gaston et al. | Jan 2009 | A1 |
| 20090010989 | Peters | Jan 2009 | A1 |
| 20090018091 | Ellis et al. | Jan 2009 | A1 |
| 20090028966 | Chen et al. | Jan 2009 | A1 |
| 20090029028 | Garcin et al. | Jan 2009 | A1 |
| 20090036491 | Tucker et al. | Feb 2009 | A1 |
| 20090041680 | Tamarkin et al. | Feb 2009 | A1 |
| 20090042819 | Ellis et al. | Feb 2009 | A1 |
| 20090048219 | Garvey | Feb 2009 | A1 |
| 20090068118 | Eini et al. | Mar 2009 | A1 |
| 20090068248 | Waterhouse et al. | Mar 2009 | A1 |
| 20090069449 | Smith et al. | Mar 2009 | A1 |
| 20090081279 | Jezek et al. | Mar 2009 | A1 |
| 20090088411 | Renzi et al. | Apr 2009 | A1 |
| 20090093510 | Clementi et al. | Apr 2009 | A1 |
| 20090098187 | Peters et al. | Apr 2009 | A1 |
| 20090108777 | Hyde et al. | Apr 2009 | A1 |
| 20090110612 | Hyde et al. | Apr 2009 | A1 |
| 20090110712 | Hyde et al. | Apr 2009 | A1 |
| 20090110933 | Hyde et al. | Apr 2009 | A1 |
| 20090110958 | Hyde et al. | Apr 2009 | A1 |
| 20090112055 | Hyde et al. | Apr 2009 | A1 |
| 20090112193 | Hyde et al. | Apr 2009 | A1 |
| 20090112197 | Hyde et al. | Apr 2009 | A1 |
| 20090118819 | Merz et al. | May 2009 | A1 |
| 20090123528 | Fossel | May 2009 | A1 |
| 20090130029 | Tamarkin et al. | May 2009 | A1 |
| 20090131342 | Ellis | May 2009 | A1 |
| 20090136410 | Smith | May 2009 | A1 |
| 20090137683 | Yasuda et al. | May 2009 | A1 |
| 20090143417 | Smith et al. | Jun 2009 | A1 |
| 20090148482 | Peters | Jun 2009 | A1 |
| 20090175799 | Tamarkin et al. | Jul 2009 | A1 |
| 20090186859 | Velázquez et al. | Jul 2009 | A1 |
| 20090191284 | Conoci et al. | Jul 2009 | A1 |
| 20090196930 | Surber et al. | Aug 2009 | A1 |
| 20090197964 | Summar et al. | Aug 2009 | A1 |
| 20090203653 | Garvey | Aug 2009 | A1 |
| 20090214618 | Schoenfisch | Aug 2009 | A1 |
| 20090214624 | Smith et al. | Aug 2009 | A1 |
| 20090214674 | Barraud et al. | Aug 2009 | A1 |
| 20090215838 | Garvey et al. | Aug 2009 | A1 |
| 20090221536 | Fossel | Sep 2009 | A1 |
| 20090222088 | Chen et al. | Sep 2009 | A1 |
| 20090226504 | Peters | Sep 2009 | A1 |
| 20090232863 | Cheng et al. | Sep 2009 | A1 |
| 20090232868 | Chen et al. | Sep 2009 | A1 |
| 20090255536 | Av-Gay et al. | Oct 2009 | A1 |
| 20090263416 | Dawson et al. | Oct 2009 | A1 |
| 20090264398 | Bauer | Oct 2009 | A1 |
| 20090270509 | Arnold et al. | Oct 2009 | A1 |
| 20090287072 | Meyerhoff et al. | Nov 2009 | A1 |
| 20090297634 | Friedman et al. | Dec 2009 | A1 |
| 20090304815 | Cossu et al. | Dec 2009 | A1 |
| 20090317885 | Mascharak | Dec 2009 | A1 |
| 20100003338 | Hubbell et al. | Jan 2010 | A1 |
| 20100015253 | Benjamin | Jan 2010 | A1 |
| 20100016767 | Jones et al. | Jan 2010 | A1 |
| 20100016790 | Peters | Jan 2010 | A1 |
| 20100021506 | Jones | Jan 2010 | A1 |
| 20100040703 | Miller et al. | Feb 2010 | A1 |
| 20100062055 | Herrmann et al. | Mar 2010 | A1 |
| 20100076162 | Ameer et al. | Mar 2010 | A1 |
| 20100086530 | Martinov | Apr 2010 | A1 |
| 20100087370 | Jain et al. | Apr 2010 | A1 |
| 20100098733 | Stasko | Apr 2010 | A1 |
| 20100099729 | Almirante et al. | Apr 2010 | A1 |
| 20100112033 | Ganzarolli de Oliveira et al. | May 2010 | A1 |
| 20100112095 | Morris et al. | May 2010 | A1 |
| 20100129474 | Benjamin et al. | May 2010 | A1 |
| 20100152683 | Lindgren et al. | Jun 2010 | A1 |
| 20100159119 | Chen et al. | Jun 2010 | A1 |
| 20100166603 | Opie | Jul 2010 | A1 |
| 20100178319 | Lindgren et al. | Jul 2010 | A1 |
| 20100184992 | Toone et al. | Jul 2010 | A1 |
| 20100196517 | Fossel | Aug 2010 | A1 |
| 20100197702 | Hellberg et al. | Aug 2010 | A1 |
| 20100197802 | Jezek et al. | Aug 2010 | A1 |
| 20100209469 | Bezwada | Aug 2010 | A1 |
| 20100210745 | McDaniel et al. | Aug 2010 | A1 |
| 20100221195 | Tamarkin et al. | Sep 2010 | A1 |
| 20100221308 | Madhyastha et al. | Sep 2010 | A1 |
| 20100233304 | Pan | Sep 2010 | A1 |
| 20100239512 | Morris et al. | Sep 2010 | A1 |
| 20100247611 | Balkus, Jr. et al. | Sep 2010 | A1 |
| 20100247680 | Szabo | Sep 2010 | A1 |
| 20100255062 | Kalivretenos et al. | Oct 2010 | A1 |
| 20100256755 | Chen et al. | Oct 2010 | A1 |
| 20100261930 | Honda et al. | Oct 2010 | A1 |
| 20100262238 | Chen et al. | Oct 2010 | A1 |
| 20100266510 | Tamarkin et al. | Oct 2010 | A1 |
| 20100268149 | Av-Gay et al. | Oct 2010 | A1 |
| 20100276284 | Meyerhoff et al. | Nov 2010 | A1 |
| 20100280122 | Fossel | Nov 2010 | A1 |
| 20100285100 | Balkus, Jr. et al. | Nov 2010 | A1 |
| 20100286272 | Perricone et al. | Nov 2010 | A1 |
| 20100286285 | Barthez et al. | Nov 2010 | A1 |
| 20100297200 | Schoenfisch et al. | Nov 2010 | A1 |
| 20100303891 | Lee et al. | Dec 2010 | A1 |
| 20100310476 | Tamarkin et al. | Dec 2010 | A1 |
| 20100311780 | Farber | Dec 2010 | A1 |
| 20100323036 | Fine | Dec 2010 | A1 |
| 20100324107 | Dos Santos et al. | Dec 2010 | A1 |
| 20100331542 | Smith | Dec 2010 | A1 |
| 20100331968 | Morris et al. | Dec 2010 | A1 |
| 20110008815 | Stamler et al. | Jan 2011 | A1 |
| 20110033437 | Smith et al. | Feb 2011 | A1 |
| 20110038965 | McKay et al. | Feb 2011 | A1 |
| 20110045037 | Tamarkin et al. | Feb 2011 | A1 |
| 20110046182 | Gilmer et al. | Feb 2011 | A1 |
| 20110059036 | Arnold et al. | Mar 2011 | A1 |
| 20110059189 | Cisneros | Mar 2011 | A1 |
| 20110065783 | O'Donnell et al. | Mar 2011 | A1 |
| 20110070318 | Jezek et al. | Mar 2011 | A1 |
| 20110071168 | Chopp et al. | Mar 2011 | A1 |
| 20110076313 | Av-Gay et al. | Mar 2011 | A1 |
| 20110086234 | Stasko et al. | Apr 2011 | A1 |
| 20110097279 | Tamarkin et al. | Apr 2011 | A1 |
| 20110104240 | Jones et al. | May 2011 | A1 |
| 20110106000 | Jones et al. | May 2011 | A1 |
| 20110195959 | Glick et al. | Aug 2011 | A1 |
| 20110212033 | Tamarkin et al. | Sep 2011 | A1 |
| 20120021055 | Schoenfisch et al. | Jan 2012 | A1 |
| 20120034169 | Schoenfisch et al. | Feb 2012 | A1 |
| 20120134951 | Stasko et al. | May 2012 | A1 |
| 20120136323 | Stasko et al. | May 2012 | A1 |
| 20120141384 | Tamarkin et al. | Jun 2012 | A1 |
| 20120237453 | Tamarkin et al. | Sep 2012 | A1 |
| 20130164225 | Tamarkin et al. | Jun 2013 | A1 |
| 20130189191 | Tamarkin et al. | Jul 2013 | A1 |
| 20130189193 | Tamarkin et al. | Jul 2013 | A1 |
| 20130189195 | Tamarkin et al. | Jul 2013 | A1 |
| 20130310533 | Bao et al. | Nov 2013 | A1 |
| 20130344334 | Schoenfisch et al. | Dec 2013 | A1 |
| 20140017121 | Schoenfisch et al. | Jan 2014 | A1 |
| 20140057001 | Bauman et al. | Feb 2014 | A1 |
| 20140065200 | Schoenfisch et al. | Mar 2014 | A1 |
| 20140105986 | Doxey et al. | Apr 2014 | A1 |
| 20140107071 | Kougoulos et al. | Apr 2014 | A1 |
| 20140134321 | Stasko et al. | May 2014 | A1 |
| 20140171395 | Schoenfisch et al. | Jun 2014 | A1 |
| 20140193502 | Tamarkin et al. | Jul 2014 | A1 |
| 20140242023 | Doxey et al. | Aug 2014 | A1 |
| 20140248219 | Tamarkin et al. | Sep 2014 | A1 |
| 20140255318 | Stasko et al. | Sep 2014 | A1 |
| 20140271494 | Tamarkin et al. | Sep 2014 | A1 |
| 20140369949 | Peters | Dec 2014 | A1 |
| 20150017103 | Tamarkin et al. | Jan 2015 | A1 |
| 20150024052 | Doxey | Jan 2015 | A1 |
| 20150025060 | Tamarkin et al. | Jan 2015 | A1 |
| 20150111973 | Bauman et al. | Apr 2015 | A1 |
| 20150118164 | Tamarkin et al. | Apr 2015 | A1 |
| 20150141606 | Bao et al. | May 2015 | A1 |
| 20150182543 | Schoenfisch et al. | Jul 2015 | A1 |
| 20150225488 | Schoenfisch et al. | Aug 2015 | A1 |
| Number | Date | Country |
|---|---|---|
| 1387542 | Dec 2002 | CN |
| 1612804 | May 2005 | CN |
| 1819848 | Aug 2006 | CN |
| 101146556 | Mar 2008 | CN |
| 101189032 | May 2008 | CN |
| 101242815 | Aug 2008 | CN |
| 101287505 | Oct 2008 | CN |
| 0 814 080 | Dec 1997 | EP |
| 0 805 678 | Oct 2003 | EP |
| 0 746 327 | Apr 2004 | EP |
| 0 724 436 | Jul 2004 | EP |
| 1 411 908 | May 2005 | EP |
| 1 163 528 | Nov 2005 | EP |
| 1 681 068 | Jul 2006 | EP |
| 1 690 532 | Aug 2006 | EP |
| 1 690 554 | Aug 2006 | EP |
| 1 690 557 | Aug 2006 | EP |
| 1 690 558 | Aug 2006 | EP |
| 1 700 611 | Sep 2006 | EP |
| 1 704 876 | Sep 2006 | EP |
| 1 704 877 | Sep 2006 | EP |
| 1 704 879 | Sep 2006 | EP |
| 1 707 224 | Oct 2006 | EP |
| 1 728 438 | Dec 2006 | EP |
| 1 731 176 | Dec 2006 | EP |
| 1 757 278 | Feb 2007 | EP |
| 1 764 119 | Mar 2007 | EP |
| 1 790 335 | May 2007 | EP |
| 1 861 130 | Sep 2008 | EP |
| 1 343 547 | Apr 2009 | EP |
| 1 871 433 | Apr 2009 | EP |
| 1 161 248 | May 2009 | EP |
| 1 846 058 | Jul 2009 | EP |
| 2 119 459 | Nov 2009 | EP |
| 2 142 179 | Jan 2010 | EP |
| 2 142 181 | Jan 2010 | EP |
| 1 917 005 | Sep 2010 | EP |
| WO 9310754 | Jun 1993 | WO |
| WO 9507691 | Mar 1995 | WO |
| WO 9510267 | Apr 1995 | WO |
| WO 9512394 | May 1995 | WO |
| WO 9519767 | Jul 1995 | WO |
| WO 9522335 | Aug 1995 | WO |
| WO 9532715 | Dec 1995 | WO |
| WO 9608966 | Mar 1996 | WO |
| WO 9613164 | May 1996 | WO |
| WO 9614844 | May 1996 | WO |
| WO 9615781 | May 1996 | WO |
| WO 9615797 | May 1996 | WO |
| WO 9627386 | Sep 1996 | WO |
| WO 9632118 | Oct 1996 | WO |
| WO 9632136 | Oct 1996 | WO |
| WO 9633757 | Oct 1996 | WO |
| WO 9635416 | Nov 1996 | WO |
| WO 9716983 | May 1997 | WO |
| WO 9731654 | Sep 1997 | WO |
| WO 9734014 | Sep 1997 | WO |
| WO 9747254 | Dec 1997 | WO |
| WO 9805689 | Feb 1998 | WO |
| WO 9806389 | Feb 1998 | WO |
| WO 9808482 | Mar 1998 | WO |
| WO 9808482 | Mar 1998 | WO |
| WO 9808496 | Mar 1998 | WO |
| WO 9813358 | Apr 1998 | WO |
| WO 9819996 | May 1998 | WO |
| WO 9820015 | May 1998 | WO |
| WO 9822090 | May 1998 | WO |
| WO 9829101 | Jul 1998 | WO |
| WO 9842661 | Oct 1998 | WO |
| WO 9900070 | Jan 1999 | WO |
| WO 9901427 | Jan 1999 | WO |
| WO 9918949 | Apr 1999 | WO |
| WO 9922729 | May 1999 | WO |
| WO 9933823 | Jul 1999 | WO |
| WO 9937616 | Jul 1999 | WO |
| WO 9944595 | Sep 1999 | WO |
| WO 9944595 | Sep 1999 | WO |
| WO 9951221 | Oct 1999 | WO |
| WO 9967210 | Dec 1999 | WO |
| WO 9967296 | Dec 1999 | WO |
| WO 0003640 | Jan 2000 | WO |
| WO 0006151 | Feb 2000 | WO |
| WO 0030658 | Jun 2000 | WO |
| WO 0033877 | Jun 2000 | WO |
| WO 0056333 | Sep 2000 | WO |
| WO 0059304 | Oct 2000 | WO |
| WO 0076318 | Dec 2000 | WO |
| WO 0112067 | Feb 2001 | WO |
| WO 0115738 | Mar 2001 | WO |
| WO 0115738 | Mar 2001 | WO |
| WO 0126702 | Apr 2001 | WO |
| WO 0126702 | Apr 2001 | WO |
| WO 0145732 | Jun 2001 | WO |
| WO 0145732 | Jun 2001 | WO |
| WO 0170199 | Sep 2001 | WO |
| WO 0185227 | Nov 2001 | WO |
| WO 0185227 | Nov 2001 | WO |
| WO 0189572 | Nov 2001 | WO |
| WO 0217880 | Mar 2002 | WO |
| WO 0217880 | Mar 2002 | WO |
| WO 0217881 | Mar 2002 | WO |
| WO 0217881 | Mar 2002 | WO |
| WO 0220026 | Mar 2002 | WO |
| WO 0220026 | Mar 2002 | WO |
| WO 0232418 | Apr 2002 | WO |
| WO 0234705 | May 2002 | WO |
| WO 0243786 | Jun 2002 | WO |
| WO 0243786 | Jun 2002 | WO |
| WO 0247675 | Jun 2002 | WO |
| WO 02051353 | Jul 2002 | WO |
| WO 02051353 | Jul 2002 | WO |
| WO 02056864 | Jul 2002 | WO |
| WO 02056864 | Jul 2002 | WO |
| WO 02056874 | Jul 2002 | WO |
| WO 02056904 | Jul 2002 | WO |
| WO 02070496 | Sep 2002 | WO |
| WO 02076395 | Oct 2002 | WO |
| WO 02076395 | Oct 2002 | WO |
| WO 03004097 | Jan 2003 | WO |
| WO 03006427 | Jan 2003 | WO |
| WO 03015605 | Feb 2003 | WO |
| WO 03015605 | Feb 2003 | WO |
| WO 03017989 | Mar 2003 | WO |
| WO 03026717 | Apr 2003 | WO |
| WO 03030659 | Apr 2003 | WO |
| WO 03041713 | May 2003 | WO |
| WO 03047636 | Jun 2003 | WO |
| WO 03047636 | Jun 2003 | WO |
| WO 03080039 | Oct 2003 | WO |
| WO 03092763 | Nov 2003 | WO |
| WO 03095398 | Nov 2003 | WO |
| WO 03095398 | Nov 2003 | WO |
| WO 2004009066 | Jan 2004 | WO |
| WO 2004009253 | Jan 2004 | WO |
| WO 2004011421 | Feb 2004 | WO |
| WO 2004012874 | Feb 2004 | WO |
| WO 2004037798 | May 2004 | WO |
| WO 2004039313 | May 2004 | WO |
| WO 2004039313 | May 2004 | WO |
| WO 2004060283 | Jul 2004 | WO |
| WO 2004064767 | Aug 2004 | WO |
| WO 2004064767 | Aug 2004 | WO |
| WO 2004087212 | Oct 2004 | WO |
| WO 2004098538 | Nov 2004 | WO |
| WO 2004098538 | Nov 2004 | WO |
| WO 2005003032 | Jan 2005 | WO |
| WO 2005004984 | Jan 2005 | WO |
| WO 2005011575 | Feb 2005 | WO |
| WO 2005011575 | Feb 2005 | WO |
| WO 2005030118 | Apr 2005 | WO |
| WO 2005030118 | Apr 2005 | WO |
| WO 2005030135 | Apr 2005 | WO |
| WO 2005030135 | Apr 2005 | WO |
| WO 2005030147 | Apr 2005 | WO |
| WO 2005030147 | Apr 2005 | WO |
| WO 2005034860 | Apr 2005 | WO |
| WO 2005034860 | Apr 2005 | WO |
| WO 2005039664 | May 2005 | WO |
| WO 2005039664 | May 2005 | WO |
| WO 2005067986 | Jul 2005 | WO |
| WO 2005070006 | Aug 2005 | WO |
| WO 2005070006 | Aug 2005 | WO |
| WO 2005070008 | Aug 2005 | WO |
| WO 2005070008 | Aug 2005 | WO |
| WO 2005070874 | Aug 2005 | WO |
| WO 2005070883 | Aug 2005 | WO |
| WO 2005072819 | Aug 2005 | WO |
| WO 2005077962 | Aug 2005 | WO |
| WO 2005077962 | Aug 2005 | WO |
| WO 2005081752 | Sep 2005 | WO |
| WO 2005081752 | Sep 2005 | WO |
| WO 2005081964 | Sep 2005 | WO |
| WO 2005094913 | Oct 2005 | WO |
| WO 2005102282 | Nov 2005 | WO |
| WO 2005107384 | Nov 2005 | WO |
| WO 2005107384 | Nov 2005 | WO |
| WO 2005112954 | Dec 2005 | WO |
| WO 2005115440 | Dec 2005 | WO |
| WO 2005115440 | Dec 2005 | WO |
| WO 2005120493 | Dec 2005 | WO |
| WO 2006023693 | Mar 2006 | WO |
| WO 2006023693 | Mar 2006 | WO |
| WO 2006037105 | Apr 2006 | WO |
| WO 2006037105 | Apr 2006 | WO |
| WO 2006041855 | Apr 2006 | WO |
| WO 2006041855 | Apr 2006 | WO |
| WO 2006045639 | May 2006 | WO |
| WO 2006055542 | May 2006 | WO |
| WO 2006055542 | May 2006 | WO |
| WO 2006058318 | Jun 2006 | WO |
| WO 2006064056 | Jun 2006 | WO |
| WO 2006066362 | Jun 2006 | WO |
| WO 2006084909 | Aug 2006 | WO |
| WO 2006084910 | Aug 2006 | WO |
| WO 2006084911 | Aug 2006 | WO |
| WO 2006084912 | Aug 2006 | WO |
| WO 2006084913 | Aug 2006 | WO |
| WO 2006084914 | Aug 2006 | WO |
| WO 2006100155 | Aug 2006 | WO |
| WO 2006095193 | Sep 2006 | WO |
| WO 2006095193 | Sep 2006 | WO |
| WO 2006096572 | Sep 2006 | WO |
| WO 2006097348 | Sep 2006 | WO |
| WO 2006099058 | Sep 2006 | WO |
| WO 2006099058 | Sep 2006 | WO |
| WO 2006100154 | Sep 2006 | WO |
| WO 2006100156 | Sep 2006 | WO |
| WO 2006100156 | Sep 2006 | WO |
| WO 2006122960 | Nov 2006 | WO |
| WO 2006122961 | Nov 2006 | WO |
| WO 2006125016 | Nov 2006 | WO |
| WO 2006125262 | Nov 2006 | WO |
| WO 2006127591 | Nov 2006 | WO |
| WO 2006127591 | Nov 2006 | WO |
| WO 2006128121 | Nov 2006 | WO |
| WO 2006128742 | Dec 2006 | WO |
| WO 2006128742 | Dec 2006 | WO |
| WO 2006128743 | Dec 2006 | WO |
| WO 2006130982 | Dec 2006 | WO |
| WO 2007003028 | Jan 2007 | WO |
| WO 2007005910 | Jan 2007 | WO |
| WO 2007005910 | Jan 2007 | WO |
| WO 2007007208 | Jan 2007 | WO |
| WO 2007012165 | Feb 2007 | WO |
| WO 2007016677 | Feb 2007 | WO |
| WO 2007016677 | Feb 2007 | WO |
| WO 2007023005 | Mar 2007 | WO |
| WO 2007023396 | Mar 2007 | WO |
| WO 2007024501 | Mar 2007 | WO |
| WO 2007024501 | Mar 2007 | WO |
| WO 2007027859 | Mar 2007 | WO |
| WO 2007028657 | Mar 2007 | WO |
| WO 2007030266 | Mar 2007 | WO |
| WO 2007030266 | Mar 2007 | WO |
| WO 2007050379 | May 2007 | WO |
| WO 2007050379 | May 2007 | WO |
| WO 2007053292 | May 2007 | WO |
| WO 2007053578 | May 2007 | WO |
| WO 2007053578 | May 2007 | WO |
| WO 2007054373 | May 2007 | WO |
| WO 2007054818 | May 2007 | WO |
| WO 2007057763 | May 2007 | WO |
| WO 2007057763 | May 2007 | WO |
| WO 2007059311 | May 2007 | WO |
| WO 2007059311 | May 2007 | WO |
| WO 2007064895 | Jun 2007 | WO |
| WO 2007064895 | Jun 2007 | WO |
| WO 2007067477 | Jun 2007 | WO |
| WO 2007084533 | Jul 2007 | WO |
| WO 2007084533 | Jul 2007 | WO |
| WO 2007086884 | Aug 2007 | WO |
| WO 2007086884 | Aug 2007 | WO |
| WO 2007088050 | Aug 2007 | WO |
| WO 2007088050 | Aug 2007 | WO |
| WO 2007088123 | Aug 2007 | WO |
| WO 2007088123 | Aug 2007 | WO |
| WO 2007092284 | Aug 2007 | WO |
| WO 2007092284 | Aug 2007 | WO |
| WO 2007100910 | Sep 2007 | WO |
| WO 2007100910 | Sep 2007 | WO |
| WO 2007103190 | Sep 2007 | WO |
| WO 2007103190 | Sep 2007 | WO |
| WO 2007127725 | Nov 2007 | WO |
| WO 2007127725 | Nov 2007 | WO |
| WO 2007133922 | Nov 2007 | WO |
| WO 2007133922 | Nov 2007 | WO |
| WO 2007143185 | Dec 2007 | WO |
| WO 2007143185 | Dec 2007 | WO |
| WO 2007149437 | Dec 2007 | WO |
| WO 2007149520 | Dec 2007 | WO |
| WO 2007149520 | Dec 2007 | WO |
| WO 2008005313 | Jan 2008 | WO |
| WO 2008005313 | Jan 2008 | WO |
| WO 2008013633 | Jan 2008 | WO |
| WO 2008013633 | Jan 2008 | WO |
| WO 2008020218 | Feb 2008 | WO |
| WO 2008027203 | Mar 2008 | WO |
| WO 2008027203 | Mar 2008 | WO |
| WO 2008032212 | Mar 2008 | WO |
| WO 2008038140 | Apr 2008 | WO |
| WO 2008038147 | Apr 2008 | WO |
| WO 2008062160 | May 2008 | WO |
| WO 2008071242 | Jun 2008 | WO |
| WO 2008088507 | Jul 2008 | WO |
| WO 2008088507 | Jul 2008 | WO |
| WO 2008095841 | Aug 2008 | WO |
| WO 2008095841 | Aug 2008 | WO |
| WO 2008098192 | Aug 2008 | WO |
| WO 2008098192 | Aug 2008 | WO |
| WO 2008100591 | Aug 2008 | WO |
| WO 2008100591 | Aug 2008 | WO |
| WO 2008110872 | Sep 2008 | WO |
| WO 2008112391 | Sep 2008 | WO |
| WO 2008112391 | Sep 2008 | WO |
| WO 2008116497 | Oct 2008 | WO |
| WO 2008116925 | Oct 2008 | WO |
| WO 2008130567 | Oct 2008 | WO |
| WO 2008141416 | Nov 2008 | WO |
| WO 2008150505 | Dec 2008 | WO |
| WO 2008152444 | Dec 2008 | WO |
| WO 2008157393 | Dec 2008 | WO |
| WO 2009007785 | Jan 2009 | WO |
| WO 2009014616 | Jan 2009 | WO |
| WO 2009014829 | Jan 2009 | WO |
| WO 2009014829 | Jan 2009 | WO |
| WO 2009019498 | Feb 2009 | WO |
| WO 2009019498 | Feb 2009 | WO |
| WO 2009019499 | Feb 2009 | WO |
| WO 2009026680 | Mar 2009 | WO |
| WO 2009036571 | Mar 2009 | WO |
| WO 2009049208 | Apr 2009 | WO |
| WO 2009056991 | May 2009 | WO |
| WO 2009064861 | May 2009 | WO |
| WO 2009064861 | May 2009 | WO |
| WO 2009072007 | Jun 2009 | WO |
| WO 2009073643 | Jun 2009 | WO |
| WO 2009073643 | Jun 2009 | WO |
| WO 2009073940 | Jun 2009 | WO |
| WO 2009073940 | Jun 2009 | WO |
| WO 2009080795 | Jul 2009 | WO |
| WO 2009086470 | Jul 2009 | WO |
| WO 2009086470 | Jul 2009 | WO |
| WO 2009087578 | Jul 2009 | WO |
| WO 2009088433 | Jul 2009 | WO |
| WO 2009090495 | Jul 2009 | WO |
| WO 2009098113 | Aug 2009 | WO |
| WO 2009098595 | Aug 2009 | WO |
| WO 2009117182 | Sep 2009 | WO |
| WO 2009117182 | Sep 2009 | WO |
| WO 2009117183 | Sep 2009 | WO |
| WO 2009124379 | Oct 2009 | WO |
| WO 2009131931 | Oct 2009 | WO |
| WO 2009155689 | Dec 2009 | WO |
| WO 2009155690 | Dec 2009 | WO |
| WO 2010002450 | Jan 2010 | WO |
| WO 2010002450 | Jan 2010 | WO |
| WO 2010033242 | Mar 2010 | WO |
| WO 2010033242 | Mar 2010 | WO |
| WO 2010045415 | Apr 2010 | WO |
| WO 2010045465 | Apr 2010 | WO |
| WO 2010048724 | May 2010 | WO |
| WO 2010080213 | Jul 2010 | WO |
| WO 2010080213 | Jul 2010 | WO |
| WO 2010096320 | Aug 2010 | WO |
| WO 2010096320 | Aug 2010 | WO |
| WO 2010114669 | Oct 2010 | WO |
| WO 2010120414 | Oct 2010 | WO |
| WO 2010151505 | Dec 2010 | WO |
| WO 2011005846 | Jan 2011 | WO |
| WO 2011022652 | Feb 2011 | WO |
| WO 2011022680 | Feb 2011 | WO |
| WO 2011061519 | May 2011 | WO |
| WO 2012153331 | Nov 2012 | WO |
| WO 2013006608 | Jan 2013 | WO |
| WO 2013138073 | Sep 2013 | WO |
| WO 2013138075 | Sep 2013 | WO |
| Entry |
|---|
| Alsantali et al., “Androgens and hair loss”, Current Opinion in Endocrinology, Diabetes & Obesity 16:246-253 (2009). |
| Amadeu et al., “Nitric Oxide Donor Improves Healing if Applied on Inflammatory and Proliferative Disease”, Journal of Surgical Research 149: 84-93 (2008). |
| Ashutosh et al., “Use of nitric oxide inhalation in chronic obstructive pulmonary disease” Thorax 55:109-113 (2000). |
| Azizzadeh et al., Nitric Oxide Improves Cisplatin Cytotoxicity in Head and Neck Squamous Cell Carcinoma, The Laryngoscope 111: 1896-1900 (2001). |
| Barbe et al. “Silica Particles: A Novel Drug-Delivery System” Advanced Materials 16(21):1959-1965 (2004). |
| Barraud et al., “Involvement of Nitric Oxide in Biofilm Dispersal of Pseudomonas aeruginosa,” Journal of Bacteriology, 2006, 188(21): 7344-7353. |
| Barst et al., “Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension”, Pulmonary Circulation, 2012, 2(2): 139-147. |
| Bellew et al., “Pathogenesis of Acne vulgaris: what's new, what's interesting and what may be clinically relevant”, Journal of Drugs in Dermatology, 2011, 10(6): 582-585. |
| Benthin et al., “Transformation of subcutaneous nitric oxide into nitrate in the rat”, Biochemical Journal, 1997, 323: 853-858. |
| Benz et al., “Effect of Nitric Oxide in Ischemia/Reperfusion of the Pancreas”, Journal of Surgical Research, 2002, 106: 46-53. |
| Bian et al., “Vascular System: Role of Nitric Oxide in Cardiovascular Diseases”, The Journal of Clinical Hypertension, 2008, 10(4): 304-310. |
| Bloch et al., “Inhaled NO as a therapeutic agent”, Cardiovascular Research, 2007, 75: 339-348. |
| Bohl Masters et al., “Effects of nitric oxide releasing vinyl poly(vinyl alcohol) hydrogel dressings on dermal wound healing in diabetic mice”, Wound Repair and Regeneration, 2002, 10(5): 286-294. |
| Bonavida et al., “Therapeutic potential of nitric oxide in cancer”, Drug Resistance Updates, 2006, 9: 157-173. |
| Bonavida et al., “Novel therapeutic applications of nitric oxide donors in cancer: Roles in chemo- and immunosensitization to apoptosis and inhibition of metastases”, Nitric Oxide, 2008, 152-157. |
| Boykin et al., “HBO Mediates Increased Nitric Oxide Production Associated With Wound Healing” Wound Repair and Regeneration 12(2):A15 (Abstract 054) (2004). |
| Boykin et al., “Hyperbaric Oxygen Therapy Mediates Increased Nitric Oxide Production Associated With Wound Healing: A Preliminary Study”, Advances in Skin & Wound Care 20(7):382-388 (2007). |
| Boykin Jr., Joseph V., “Wound Nitric Oxide Bioactivity: A Promising Diagnostic Indicator for Diabetic Foot Ulcer Management”, Journal of Wound, Ostomy & Continence Nursing 37(1):25-32 (2010). |
| Brennan et al., “The role of nitric oxide in oral diseases”, Archives of Oral Biology, 2003, 48: 93-100. |
| Bruch-Gerharz et al. “Nitric Oxide in Human Skin: Current Status and Future Prospects” The Journal of Investigative Dermatology, 1998, 110(1): 1-7. |
| Cals-Grierson et al., “Nitric oxide function in the skin”, Nitric Oxide, 2004, 10: 179-193. |
| Carlsson et al., “Intravesical Nitric Oxide Delivery for Prevention of Catheter-Associated Urinary Tract Infections”, Antimicrobial Agents and Chemotherapy, 2005, 49(6): 2352-2355. |
| Chen et al., “Cutaneous Androgen Metabolism: Basic Research and Clinical Perspectives”, The Journal of Investigative Dermatology, 2002, 119(5): 992-1007. |
| Coban et al. “The Effect of Nitric Oxide Combined with Fluoroquinolones against Salmonellaenterica Serovar Typhimurium in Vitro” Mem. Inst. Oswaldo Cruz, 2003, 98(3): 419-423. |
| Davies et al. “Chemistry of the Diazeniumdiolates. 2. Kinetics and Mechanism of Dissociation to Nitric Oxide in Aqueous Solution” Journal of the American Chemical Society 123(23):5473-5481 (2001). |
| De Groote et al. “NO Inhibitors: Antimicrobial Properties of Nitric Oxide” Clinical Infectious Diseases, 1995, 21(Suppl. 2): S162-S165. |
| Deeb et al., “Inducible Nitric Oxide Synthase Mediates Prostaglandin H2 Synthase Nitration and Suppresses Eicosanoid Production”, American Journal of Pathology, 2006, 168(1): 349-362. |
| Del Punta et al., “Nitric Oxide Inhibits Leydig Cell Steroidogenesis”, Endocrinology, 1996, 137(12): 5337-5343. |
| Di Costanzo et al., “Crystal Structure of Human Liver Δ4-3-Ketosteroid 5β-Reductase (AKR1D1) and Implications for Substrate Binding and Catalysis”, The Journal of Biological Chemistry, 2008, 283(24): 16830-16839. |
| Dobmeier et al. “Antibacterial Properties of Nitric Oxide-Releasing Sol-Gel Microarrays” Biomacromolecules 5(6):2493-2495 (2004). |
| Drewett et al., “Nitric oxide potently inhibits the rate-limiting enzymatic step I steroidogenesis”, Molecular and Cellular Endocrinology, 2002, 194: 39-50. |
| Fang, Ferric, “Mechanisms of Nitric Oxide-related Antimicrobial Activity”, Journal of Clinical Investigation, 1997, 99(12): 2818-2825. |
| Farias-Eisner et al., “The Chemistry and Tumoricidal Activity of Nitric Oxide/Hydrogen Peroxide and the Implications to Cell Resistance/Susceptibility”, The Journal of Biological Chemistry, 1996, 271(11): 6144-6151. |
| Frederiksen et al., “Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling”, Clinical Cancer Research, 2007, 13: 2199-2206. |
| Fritsch et al., “Sebocytes are the Key Regulators of Androgen Homeostasis in Human Skin”, Journal of Investigative Dermatology, 2001, 116: 793-800. |
| Garza et al., “Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells”, The Journal of Clinical Investigation, 2011, 121(2): 613-622. |
| Garza et al. “Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenic alopecia” Science Translation Medicine 4(126):1-21 (2012). |
| Ghaffari et al., “Potential application of gaseous nitric oxide as a topical antimicrobial agent”, Nitric Oxide, 2006, 14(1): 21-29. |
| Gharavi et al., “Role of Endothelial Nitric Oxide Synthase in the Regulation of SREBP Activation by Oxidized Phospholipids”, Circulation Research, 2006, 98: 768-776. |
| Giacomoni et al., “Gender-linked differences in human skin”, Journal of Dermatological Science, 2009, 55(3): 144-149. |
| Goodwin et al., “Nitric Oxide Trapping of Tyrosyl Radicals Generated during Prostaglandin Endoperoxide Synthase Turnover” The Journal of Biological Chemistry, 1998, 273(15): 8903-8909. |
| Goodwin et al., “Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis”, The FASEB Journal, 1999, 13: 1121-1136. |
| Griffin et al. “The Androgen Resistance Syndromes: 5α-Reductase Deficiency, Testicular Feminization, and Related Disorders”, The Metabolic Basis of Inherited Disease II, Sixth Edition, 1989, McGraw-Hill, New York: 1919-1944. |
| Gupta et al., “Bioactive materials for biomedical applications using sol-gel technology”, Biomedical Materials 3: 1-15 (2008). |
| Hamilton, James, “Male Hormone Stimulation is Prerequisite and an Incitant in Common Baldness”, American Journal of Anatomy, 1942, 71: 451-480. |
| Hanke et al. “Nitric Oxide Inhibits Aldosterone Synthesis by a Guanylyl Cyclase-Independent Effect” Endocrinology 139(10):4053-4060 (1998). |
| Hatton et al. “Past, Present, and Future of Periodic Mesoporous Organosilicas—The PMOs” Accounts of Chemical Research 38(4):305-312 (2005). |
| Herman et al., “Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis”, European Heart Journal, 2005, 26: 1945-1955. |
| Herman et al. “Systemic Administration of Alcohol to Adult Rats Inhibits Leydig Cell Activity: Time Course of Effect and Role of Nitric Oxide” Alcoholism: Clinical and Experimental Research 30(9):1479-1491 (2006). |
| Hetrick et al., “Reducing Implant-Related Infections: Active Release Strategies”, Chemical Society Reviews 36: 780-789 (2006). |
| Hetrick et al., “Antibacterial Nitric Oxide-Releasing Xerogels: Cell Viability and Parallel Plate Flow Cell Adhesion Studies”, Biomaterials 28(11): 1948-1956 (2007). |
| Hetrick et al., “Bactericidal Efficacy of Nitric Oxide-Releasing Silica Nanoparticles”, ACS Nano 2(2): 235-246 (2008). |
| Hetrick et al., “Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles”, Biomaterials, 2009, 30: 2782-2789. |
| Hirst et al., “Targeting nitric oxide for cancer therapy”, Journal of Pharmacy and Pharmacology, 2007, 59: 3-13. |
| Howlin et al., “Nitric oxide-mediated dispersal and enhanced antibiotic sensitivity in Pseudomonas aeruginosa biofilms from the cystic fibrosis lung”, Archives of Disease in Childhood, 2011, 96: A45. |
| Hrabie et al., “Chemistry of the nitric oxide-releasing diazeniumdiolate (‘nitrosohydroxylamine’) functional group and its oxygen-substituted derivatives”, Chemical Reviews 102: 1135-1154 (2002). |
| Huerta et al., “Nitric oxide donors: Novel cancer therapeutics (Review)”, International Journal of Oncology, 2008, 33: 909-927. |
| Imperato-McGinley et al., “The Androgen Control of Sebum Production. Studies of Subjects With Dihydrotestosterone Deficiency and Complete Androgen Insensitivity”, Journal of Endocrinology and Metabolism, 1993, 76(2): 524-528. |
| International Preliminary Report on Patentability Corresponding to International Application No. PCT/US2009/005643; Mailed Apr. 28, 2011. |
| International Preliminary Report on Patentability Corresponding to International Application No. PCT/US2010/046173; Mailed Mar. 1, 2012. |
| International Preliminary Report on Patentability Corresponding to International Application No. PCT/US2011/065043; Mailed Jun. 27, 2013. |
| International Preliminary Report on Patentability Corresponding to International Application No. PCT/US2013/028215; Mailed Sep. 16, 2014. |
| International Search Report and the Written Opinion of the International Searching Authority Corresponding to International Application No. PCT/US2009/005643; Mailed May 24, 2010. |
| International Search Report and the Written Opinion of the International Searching Authority Corresponding to International Application No. PCT/US2010/046173; Mailed Dec. 6, 2010. |
| International Search Report and the Written Opinion of the International Searching Authority Corresponding to International Application No. PCT/US2010/052460; Mailed Jan. 24, 2011. |
| International Search Report and the Written Opinion of the International Searching Authority Corresponding to International Application No. PCT/US2010/046209; Mailed May 23, 2011. |
| International Search Report and the Written Opinion of the International Searching Authority Corresponding to International Application No. PCT/US2011/065043; Mailed Apr. 24, 2012. |
| International Search Report and the Written Opinion of the International Searching Authority Corresponding to International Application No. PCT/US2012/045384; Mailed Nov. 5, 2012. |
| International Search Report and the Written Opinion of the International Searching Authority Corresponding to International Application No. PCT/US2012/045390; Mailed Dec. 11, 2012. |
| International Search Report and the Written Opinion of the International Searching Authority Corresponding to International Application No. PCT/US2013/028215; Mailed Apr. 29, 2013. |
| Inui et al. “Androgen actions on the human hair follicle: perspectives” Experimental Dermatology 22:168-171 (2012). |
| Iwakiri et al., “Synthesis of amphiphilic polysiloxanes and their properties for formation of nano-aggregates”, Colloid and Polymer Science 287: 577-582 (2009). |
| Jobgen et al., “Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates”, Journal of Nutritional Biochemistry, 2006, 17: 571-588. |
| Johnson et al., “Reduced ischemia/reperfusion injury via glutathione-initiated nitric oxide-releasing dendrimers”, Nitric Oxide, 2010, 22(1): 30-36. |
| Jones et al. “Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices”, Applied Microbiology and Biotechnology, 2010, 88: 401-407. |
| Kelce et al., “Persistent DDT metabolite p,p′-DDE is a potent androgen receptor antagonist”, Nature,1995, 375: 581-585. |
| Kiziltepe et al., “JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells”, Blood, 2007, 110: 709-718. |
| Lai et al. “The role of androgen and androgen receptor in skin-related disorders” Archives of Dermatological Research 304(7):499-510 (2012). |
| Lamanna et al., “D-Aspartic acid and nitric oxide as regulators of androgen production in boar testis”, Theriogenology, 2007, 67: 249-254. |
| Lamas et al., “Nitric oxide signaling comes of age: 20 years and thriving”, Cardiovascular Research, 2007, 75: 207-209. |
| Lin et al., “Structural and Morphological Control of Cationic Surfectant-Templated Mesoporous Silica”, Accounts of Chemical Research, 2002, 35(11): 927-935. |
| Liu et al., “Nitric Oxide Inhalation Improves Microvascular Flow and Decreases Infarction Size After Myocardial Ischemia and Reperfusion”, Journal of the American College of Cardiology, 2007, 50(8): 808-817. |
| Living Water Acid-Alkaline Balance http://www.livingwaterhealthsolutions.com/Articles/alkalize.php, accessed online: Nov. 3, 2011. |
| Lucky et al., “Hair Follicle Response of the Golden Syrian Hamster Flank Organ to Continuous Testosterone Stimulation Using Silastic Capsules”, The Journal of Investigative Dermatology, 1986, 86(1): 83-86. |
| Luo et al., “Nitric oxide: a newly discovered function on wound healing”, Acta Pharmacologica Sinica, 2005, 26(3): 259-264. |
| Marxer et al., “Sol-Gel Derived Nitric Oxide-Releasing Oxygen Sensors”, The Analyst, 2005, 130(2): 206-212. |
| Masuda et al. “Nitric oxide inhibits steroidogenesis in cultured porcine granulosa cells” Molecular Human Reproduction 3(4):285-292 (1997). |
| Masuda et al. “Effects of nitric oxide on steroidogenesis in porcine granulosa cells during different stages of follicular development” European Journal of Endocrinology 144:303-308 (2001). |
| McElhaney-Feser et al., “Synergy of Nitric Oxide and Azoles against Candida Species In Vitro,” Antimicrobial Agents and Chemotherapy 42(9) 2342-2346 (1998). |
| McGrowder et al., “Therapeutic Uses of Nitric Oxide-donating Drugs in the Treatment of Cardiovascular Diseases”, International Journal of Pharmacology, 2006, 2(4): 366-373. |
| Miller et al. “The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders” Endocrine Reviews 32(1):81-151 (2011). |
| Minamiyama et al., “Irreversible Inhibition of Cytochrome P450 by Nitric Oxide”, Journal of Pharmacology and Experimental Therapeutics, 1997, 283(3): 1479-1485. |
| Morgan et al., “Cytochromes P450 and Flavin Monooxygenases—Targets and Sources of Nitric Oxide”, Drug Metabolism and Disposition, 2001, 29: 1366-1376. |
| Nablo et al., “Inhibition of Implant-Associated Infections via Nitric Oxide Release”, Biomaterials, 2005, 26(34): 6984-6990. |
| Nablo et al., “Nitric Oxide-Releasing Sol-Gels as Antibacterial Coatings for Orthopedic Implants”, Biomaterials, 2005, 26(8): 917-924. |
| Napoli et al., “Nitric oxide and atherosclerosis: An update”, Nitric Oxide, 2006, 15(4): 265-279. |
| Office Action corresponding to Chinese Patent Application No. 201080047713.3; dated Feb. 28, 2013. |
| Office Action corresponding to Chinese Patent Application No. 201080047713.3; dated May 27, 2014. |
| Office Action corresponding to Chinese Patent Application No. 201180060338.0; date of mailing: Jun. 30, 2014. |
| Panesar et al. “Decreased Steroid Hormone Synthesis from Inorganic Nitrite and Nitrate: Studies in Vitro and in Vivo” Toxicology and Applied Pharmacology 169:222-230 (2000). |
| Pawin et al., “Physiopathology of acne vulgaris: recent data, new understanding of the treatments”, European Journal of Dermatology, 2004, 14: 4-12. |
| Phillips et al., “Nitric Oxide Mechanism of Protection in Ischemia and Reperfusion Injury”, Journal of Investigative Surgery, 2009, 22: 46-55. |
| Pomerantz et al., “Nitric Oxide Is a Mediator of the Inhibitory Effect of Activated Macrophages on Production of Androgen by the Leydig Cell of the Mouse”, Endocrinology, 1998, 139(3): 922-931. |
| Puerto et al., “Regional scalp differences of the androgenic metabolic pattern in subjects affected by male pattern baldness”, Revista Espanola de Fisiologia, 1990, 46(3): 289-296. |
| Pulfer et al., “Incorporation of Nitric Oxide-Releasing Crosslinked Polyethyleneimine Microspheres Into Vascular Grafts”, Journal of Biomedical Materials Research, 1997, 37(2): 182-189. |
| Reynolds et al., “Nitric Oxide-Releasing Hydrophobic Polymers: Preparation, Characterization, and Potential Biomedical Applications”, Free Radical Biology and Medicine, 2004, 37(7): 926-936. |
| Robson, Martin, “Wound Infection: A Failure of Wound Healing Caused by an Imbalance of Bacteria,” Surgical Clinics of North America, 1997, 77(3): 637-50. |
| Roediger et al., “Inhibition of Hepatocyte Lipogenesis by Nitric Oxide Donor: Could Nitric Oxide Regulate Lipid Synthesis?”, Life, 2004, 56(1): 35-40. |
| Rosenfield, Robert L., “Hirsutism and the Variable Response of the Pilosebaceous Unit to Androgen”, Journal of Investigative Dermatology Symposium Proceedings, 2005, 10(3): 205-208. |
| Rosignoli et al., “Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo”, Experimental Dermatology, 2003, 12: 480-489. |
| Rothrock et al., “Synthesis of Nitric Oxide-Releasing Gold Nanoparticles”, Journal of the American Chemical Society, 2005, 127(26): 9362-9363. |
| Saavedra et al., “Esterase-Sensitive Nitric Oxide Donors of the Diazeniumdiolate Family: In Vitro Antileukemic Activity”, Journal of Medicinal Chemistry, 2000, 43, 261-269. |
| Salivary pH Testing: https://allicincenter.com/pdf/ph—testing.pdf, Accessed online Nov. 3, 2011. |
| Sangster, James “Octanol-Water Partition Coefficients of Simple Organic Compounds” Journal of Physical and Chemical Reference Data 18(3):1111-1227 (1989). |
| Sansone et al., “Differential Rates of Conversion of Testosterone to Dihydrotestosterone in Acne and in Normal Human Skin—A Possible Pathogenic Factor in Acne”, Journal of Investigative Dermatology, 1971, 56: 366-372. |
| Saral et al., “The Equilibrium Between Endothelin-1/Nitric Oxide in Acne Vulgaris,” Istanbul Tip Fakultesi Dergisi Cilt, 2008, 71(4): 101-105. |
| Sato et al., “Dynamic Aspect of Reactive Oxygen and Nitric Oxide in Oral Cavity”, Journal of Clinical Biochemistry and Nutrition, 2008, 42: 8-13. |
| Schaffer et al., “Diabetes-impaired healing and reduced wound nitric oxide synthesis: A possible pathophysiologic correlation”, Surgery, 1997, 121(5):513-519. |
| Schairer et al., “The potential of nitric oxide releasing therapies as antimicrobial agents”, Virulence, 2012, 3(3): 271-279. |
| Schulz et al., “Nitric oxide in myocardial ischemia/reperfusion injury”, Cardiovascular Research, 2004, 61: 402-413. |
| Schwentker et al., “Nitric oxide and wound repair: role of cytokines?” Nitric Oxide, 2002, 7(1): 1-10. |
| Shi et al. “The role of iNOS in wound healing”, Surgery, 2001, 130(2): 225-229. |
| Shin et al. “Nitric Oxide-Releasing Sol-Gel Particle/Polyurethane Glucose Biosensors”, Analytical Chemistry 76: 4543-4549 (2004). |
| Shin et al. “Synthesis of Nitric Oxide-releasing Silica Nanoparticles” Journal of the American Chemical Society 129:4612-4619 (2007). |
| Simeone et al., “N-(4-Hydroxyphenyl) retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells” Carcinogenesis, 2006, 27(3): 568-577. |
| Siriussawakul et al., “Role of nitric oxide in hepatic ischemia-reperfusion injury”, World Journal of Gastroenterology, 2010, 16(48): 6079-6086. |
| Slominski et al. “Steroidogenesis in the skin: implications for local immune functions” The Journal of Steroid Biochemistry and Molecular Biology 137:107-123 (2013). |
| Slowing et al. “Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers”, Advanced Drug Delivery Reviews, 2008, 60: 1278-1288. |
| Smith et al. “Transdermal delivery of nitric oxide from diazeniumdiolates” Journal of Controlled Release 51:153-159 (1998). |
| Smith et al. “Sebaceous gland lipids: friend or foe?” Journal of Lipid Research, 2008, 49: 271-281. |
| Snyder et al., “Nitric Oxide Inhibits Aromatase Activity: Mechanisms of Action”, The Journal of Steroid Biochemistry and Molecular Biology, 1996, 58(1): 63-69. |
| Stasko et al., “Dendrimers as a Scaffold for Nitric Oxide Release”, Journal of the American Chemical Society, 2005, 128: 8265-8271. |
| Stein et al., “Hybrid Inorganic Organic Mesoporous Silicates Nanoscopic Reactors Coming of Age”, Advanced Materials, 2000, 12(19): 1403-1419. |
| Stevens et al. “Nitric Oxide-Releasing Silica Nanoparticle Inhibition of Ovarian Cancer Cell Growth” Molecular Pharmaceutics 7(3):775-785 (2010). |
| Summersgill et al., “Killing of Legionella pneumophila by nitric oxide in γ-interferon-activated macrophages”, Journal of Leukocyte Biology, 1992, 52: 625-629. |
| Tang et al. “Synthesis of Beta-Lactamase Activated Nitric Oxide Donors” Bioorganic & Medicinal Chemistry Letters 13:1687-1690 (2003). |
| Terpolilli et al. “Inhalation of Nitric Oxide Prevents Ischemic Brain Damage in Experimental Stroke by Selective Dilatation of Collateral Arterioles” Circulation Research 110:727-738 (2012). |
| Thiboutot, Diane, “New Treatments and Therapeutic Strategies for Acne” Archives of Family Medicine 9:179-187 (2000). |
| Thiboutot et al. “Human Skin is a Steroidogenic Tissue: Steroidogenic Enzymes are Cofactors Are Expressed in Epidermis, Normal Sebocytes, and an Immortalized Sebocyte Cell Line (SEB-1)” The Journal of Investigative Dermatology 120(6):905-914 (2003). |
| Thiboutot et al. “New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne Group” Journal of the American Academy of Dermatology 60(5): S1-S50 (2009). |
| Thomas et al. “Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide” PNAS 101(24): 8894-8899 (2004). |
| Weller, Richard, “Nitric oxide donors and the skin: useful therapeutic agents?” Clinical Science, 2003, 105: 533-535. |
| Wink et al. “The multifaceted roles of nitric oxide in cancer” Carcinogenesis, 1998, 19(5):711-721. |
| Witte et al., “Nitric oxide enhances experimental wound healing in diabetes”, British Journal of Surgery, 2002, 89: 1594-1601. |
| Witte et al., “Role of nitric oxide in wound repair”, The American Journal of Surgery, 2002, 183(4): 406-412. |
| Wong et al., “Androgen Receptor Antagonist versus Agonist Activities of the fungicide Vinclozolin relative to Hydroxyflutamide”, The Journal of Biological Chemistry 270(34): 19998-20003 (1995). |
| Yatera et al., “Severe dyslipidaemia, atherosclerosis, and sudden cardiac death in mice lacking all NO synthases fed a high-fat diet”, Cardiovascular Research 87: 675-682 (4 pages of supplementary figures) (2010). |
| Yetik-Anacak et al. “Nitric oxide and the endothelium: History and impact on cardiovascular disease”, Vascular Pharmacology 45(5): 268-276 (2006). |
| Zhang et al., “Nitric Oxide-Releasing Fumed Silica Particles: Synthesis, Characterization, and Biomedical Application”, Journal of the American Chemical Society 125: 5015-5024 (2003). |
| Zhu et al. “Corrosion protection of metals by water-based silane mixtures of bis-[trimethoxysilylpropyl]amine and vinyltriacetoxysilane” Progress in Organic Coatings 49: 42-53 (2004). |
| Zhu et al. “Nitric Oxide Accelerates the Recovery from Burn Wounds”, World Journal of Surgery 31: 624-631 (2007). |
| Zhu et al. “Effects of Nitric Oxide on Skin Burn Wound Healing” Journal of Burn Care & Research 29(5): 804-814 (2008). |
| Number | Date | Country | |
|---|---|---|---|
| 20170056437 A1 | Mar 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61235933 | Aug 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13256928 | US | |
| Child | 15353301 | US |
